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Summary
This thesis is an account of studies designed to test 
the hypothesis that Human Immunodeficiency virus (HIV) 
infection in women predisposes to the development of 
cervical intraepithelial neoplasia (CIN) by allowing the 
unchecked action of oncogenic viruses. Fifty HIV seropos- 
tive women, for 43 of whom there were HIV seronegative 
case matched controls were studied by cytology, colposco­
py, and histology. Investigations were carried out to 
detect the presence of oncogenic viruses Human Papilloma 
virus (HPV), Epstein Barr virus (EBV) and Herpes Simplex 
virus (HSV). A secondary hypothesis, that the development 
of CIN is related to immunosuppression was tested at both 
a systemic and local level. At a local level immune 
funtion was investigated by measuring the Langerhans1 
cell number, and relating it to the presence or absence 
of CIN and to generalised immunosuppression.
There was no significant difference in the prevalence 
of CIN (6/43 (14% (95% Confidence Interval: 5-28%))
versus 4/43 (9% (95% Confidence Interval: 3-28%))) or
detectable cervical infection with oncogenic viruses 
between HIV seropositive and HIV seronegative patients. 
However, if the HIV infected women showed signs of immu- 
nosupression, as detected clinically, or measured by T4 
count, beta 2 microglobulin, and p24 antigen the inci­
dence of CIN was increased. An association between de­
pressed local cervical epithelial immunity and HIV relat­
ed immunosuppression was demonstrated, but this was not 
shown to be related to CIN. In this study HIV infection
9
per se did not appear to increase significantly 
of CIN developing, but immunosuppression as a 
HIV infection did increase this risk.
the risk 
result of
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Chapter 1.
General Introduction
I have worked in the fields of gynaecology and genitouri­
nary medicine since General Medical Council registration. 
I undertook the elective year of RCOG training in geni­
tourinary medicine in St Mary's Hospital, London W2, in 
1984/1985. At this time the first substantial numbers of 
cases of HIV related disease in the UK were diagnosed in 
the department of Genitourinary medicine at St. Mary's 
and as a Senior House Officer in the unit I assisted in 
their management. Thereafter, I returned to a gynaecology 
post in Glasgow. At this time under the supervision of Dr 
J Davis in Stobhill Hospital, I developed an interest in 
colposcopy and undertook a study to determine the preva­
lence of sexually transmitted diseases in patients with 
normal and abnormal cervical cytology (1). Thereafter I 
was employed in Bellshill Hospital, where HIV, although 
not prevalent in the local population at that time stimu­
lated much anxiety on the part of both medical and mid­
wifery staff with regard to patient to staff transmis­
sion of the virus which, although extremely rare appeared 
to have occurred through needle stick injury. Whilst not 
investigating the incidence of needlestick injury direct­
ly, I undertook a study to determine the incidence of 
glove puncture at Caesarean section (2). After obtaining 
membership of the Royal College of Obstetricians and 
Gynaecologists I was keen to combine the above interests 
and was fortunate to obtain a research post which allowed
13
this. The research post was based jointly in the depart­
ments of Gynaecology and Genitourinary medicine at St 
Mary’s Hospital. The project was funded by the AIDS virus 
education and research trust (AVERT), a charitable organ­
isation aimed at promoting HIV research, primarily, in 
the often ignored area of HIV in women.
I was responsible for organising and coordinating the 
overall study and specifically for the clinical aspects 
of the study in collaboration with Mr Mark Botcherby much 
of the laboratory analysis.
The study was designed to test the following hypotheses:
(i) that HIV infection predisposed to cervical neoplasia,
(ii) that this cervical neoplasia would be as a direct 
result of HIV related immunosuppression,
and/or
(iii) that this cervical neoplasia might be as a result 
of immunosuppression causing increased expression of HPV 
and EBV in previously infected cervical epithelium, 
and/or
(iv) as a result of decreased immune surveillance in the 
cervix.
Chapter 2. 
Literature Review
(i) Introduction
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An unusually high incidence of CIN has been reported in 
patients infected with HIV (3, 4, 5, 6, 7, 8, 11, 12). 
However, most of these studies were uncontrolled and 
may only have reflected an increased exposure of the 
subjects to recognised risk factors, such as age at first 
sexual intercourse, number of sexual partners and smok­
ing. At the inception of the study an exhaustive litera­
ture search confirmed that a study with a control group 
had not been performed to determine which factors were 
predisposing HIV seropositive women to an apparent in­
crease in CIN. The following review of the literature is 
divided into six sections each dealing with a different 
background component to the above hypotheses.
(ii) HIV and CIN
Uncontrolled observation has suggested that lower genital 
tract neoplasia is more common in HIV infected women than 
in those not infected (3, 4, 5, 6, 7, 8, 11, 12). Brad- 
beer (3) reported the first series of HIV positive women 
studied for CIN. In this study 11 patients were enrolled 
and studied by cytology, of these 9 were also studied by 
colposcopy and colposcopically directed biopsy. Of the 11 
patients 2 had CDC stage 4 disease. The putative mode of 
HIV transmission in this group was that 3 patients were 
from sub-Saharan Africa, 5 were IVDUs. Nine of the 11 
patients had changes suggestive of CIN on cytology and / 
or histology and 8 of these 9 patients had CIN confirmed 
on histology. No control group was recruited, the only 
comparison possible was with routine cytological examina­
tion performed within the same GUM clinic which showed an
15
8% prevalence of dyskaryosis. This report suffers from 
certain problems when it comes to interpreting why 82% of 
patients infected with HIV should have changes suggestive 
of CIN:
(a) Risk factors for CIN in the HIV seropositive patients 
were not established.
(b) Laboratory measurements of immunosuppression were not 
made.
(c) The control group was not specifically selected to 
match the HIV seropositive patients for CIN risk factors.
(d) The number of patients recruited to the study was 
small.
Following Bradbeer's report three further letters were 
published in the Lancet:
Spurrett et al (4) reported results on 10 patients who 
had contracted HIV infection by different means from 
those described by Bradbeer: 2 by heterosexual transmis­
sion, 6 by blood transfusion and 2 by artificial insemi­
nation. Of these patients, 5 had CIN on histological 
examination. Of these 5 patients with CIN, none had AIDS. 
T4 / T8 counts were performed which showed a possible 
trend towards an association between a low T4 count and 
the presence of CIN. This report whilst showing a lesser 
prevalence of CIN than Bradbeer still demonstrates a high 
prevalence of abnormality (50%). This study also has 
small patient numbers, lack of quantification of CIN risk 
factors and lack of any control group.
Crocchiolo et al (5) reported a larger series of 24 
patients in whom 22 had acquired HIV by IVDU and 2 by 
heterosexual contact. In this study 2 patients had CIN on
16
histological examination and a further patient had CIN 
on cytology not confirmed by histology. Twenty two of 
their patients had evidence of koilocytosis which they 
took as evidence of HPV infection. No in-situ hybridisa­
tion techniques were used to confirm the diagnosis or 
subtype of HPV which may well have led to overdiagnosis 
of HPV infection. Sixteen of their patients were CDC 
stage 2 and 3 and 8 were CDC stage 4. They failed to show 
any association between immunosuppression as quantified 
clinically, or by laboratory measurement and CIN or HPV 
infection. Although the authors compared the prevalence 
of HPV infection with their general population (3% preva­
lence) and their colposcopy clinic population (32% preva­
lence) they had not quantified their HIV infected pa­
tients in terms of recognised CIN risk factors and had 
not enrolled an appropriate control group.
Byrne et. a_l (6) reported a review of their 15 HIV 
seropositive patients attending the GUM clinic at St 
Mary's Hospital, London W 2 . Eleven patients had normal 
cervical cytology and 4 (36%) had cytology suggestive of 
CIN; this compared with a 12% prevalence of abnormal 
smears in the routine GUM clinic population. The 4 pa­
tients with abnormal cytology had histological examina­
tion performed confirming the presence of CIN. It was 
also noted that 2 had VIN and 1 had vulval papilloma 
virus infection. This study again suffered from the lack 
of an appropriately selected control group. The colpo- 
scopic examination of only those patients with abnormal 
cytology may have led to an underestimate of the preva­
lence of CIN, VIN and VAIN. Again no attempt was made to
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quantify immunosuppression either by clinical features or 
laboratory measurement.
More recently Henry et al (7) described an association 
between HIV, HPV and CIN. This study was based on 4 
patients attending their general practitioner. They 
showed that all 4 patients had histological evidence of 
koilocytosis and CIN. Their study however comprised 
inadequate patient numbers, no control group, no labora­
tory measurement of immunosuppression and histological 
evidence of HPV infection in the absence of laboratory 
confirmation .
Monfardini et al (8) reported 49 HIV infected patients 
with unusual malignant tumours of whom 9 had evidence of 
cervical dysplasia, invasive in one case. All were IVDUs 
and only one had evidence of immunosuppression clinical­
ly. This report is again small and uncontrolled with no 
laboratory measurement of immunosuppression.
Two studies (9, 10) of anogenital / rectal dysplasia 
(AIN) have been performed in HIV seropositive men. Whilst 
there are thought to be similarities between CIN and 
AIN, these are not fully understood. These studies again 
suffered from lack of appropriately selected control 
groups.
More recently Byrne et al_ (11) have reported a larger 
series of 19 HIV seropositive patients. Of these 4 had 
histologically proven CIN. This study had no HIV seroneg­
ative control group and HPV detection was performed 
colposcopically, cytologically and histologically, in the 
absence of DNA hybridisation techniques. No attempt was 
made to measure the degree of HIV related immunosuppres­
18
sion in these patients.
In 1991 Shafer et a_l (12) reported the first major 
study which included a control group. They enrolled 111 
HIV seropositive women and studied them by cytology, 
colposcopy, and histology. The control group comprised 76 
HIV seronegative intravenous drug users and 526 women 
(HIV untested) attending the colposcopy clinic. CIN was 
shown in 41% of the HIV infected women compared to 9% of 
the HIV seronegative drug users, and 4% of the HIV un­
tested clinic attenders. Frequency and severity of cervi­
cal dysplasia appeared to increase with diminishing 
numbers of T4 cells. The investigators selected two 
control groups to maximise their chances of controlling 
for CIN risk factors, The HIV untested group, as the 
authors admit, is particularly unlikely to be comparable. 
It is also possible that some of this group may them­
selves be HIV seropositive. No attempt was made to detect 
other potentially oncogenic viruses apart from HPV which 
was detected by koilocytosis alone.
Conclusions
The above papers confirmed that no study with quantifica­
tion of CIN risk factors, the enrolment of a suitable HIV 
seronegative control group, appropriate measurement of 
immunosuppression and sub-typing of HPV infection had 
been performed.
(iii) Tumours and immunosuppression
An increased incidence of neoplasia has long been noted 
in patients with primary and acquired j immunosuppression
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(13). This association will be discussed, however, HIV 
related tumours will be described only briefly in this 
section of the text. Many studies have shown an increased 
incidence of CIN (14, 15, 16, 17) in patients with immu­
nosuppression, particularly in patients on immunosuppres­
sive therapy following renal transplantation.
Inherited cellular immune defects are associated with 
an increased risk of neoplasia: in one study of the
Wiskott-Aldrich syndrome the prevalence of malignancy was 
15.4% and in ataxia-telangiectasia was 11.7% (18). Pa­
tients with acquired immunodeficiency secondary to cyto­
toxic or immunosuppressive therapy given for both malig­
nant and non-malignant disease also have an increased 
risk of malignancy. Renal transplant recipients have a 
much greater incidence of neoplasia when compared to an 
age matched control group. These tumours comprise lympho­
mas, leukaemias and carcinomas. Cervical carcinoma has a 
13 fold increase in incidence in organ transplant pa­
tients (19). Porreco et al (20) in renal allograft pa­
tients reported a 14 fold increase in the prevalence of 
CIN over the prevalence in women of the same age in the 
general population. HIV is associated with Kaposi's 
sarcoma, malignant non-Hodgkin's lymphoma, Hodgkin's 
disease and malignant oral carcinoma (21).
Cordiner et al (14) reported a series of 26 immunosup- 
pressed patients post renal transplant on varying doses 
of prednisolone and azathioprine. The patients had been 
immunosuppressed for 6 months to 8 years. Five patients 
(19.2%) had histological evidence of CIN. At that time 
the detection rate of abnormal cervical cytology in the
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West of Scotland was 0.3-0.5%, clearly much lower than 
that found in the immunosuppressed patients studied. 
MacLean et al (15) |reported on 31 patients, 24 of whom
! were | immunosuppressed and 5 (21%) had evidence of
]
HPV infection on cytology and / or histology, although 
none of the patients had CIN. Schneider et al (16) stud­
ied 132 patients who had received renal transplants and 
found that 11 (8.5%) had cervical condylomata and 6 
(4.5%) of these 11 had CIN.
In none of these studies was a comparable non immuno­
suppressed control group matched for CIN risk factors 
enrolled. Neither was laboratory quantification of immu­
nosuppression undertaken, nor with the exception of 
McLean's study was the immunosuppressive therapy quanti­
fied. These factors make estimation of the exact level 
and influence of immunosuppression difficult. Diagnosis 
of HPV infection in all studies was made by the presence 
of koilocytosis on cytology and / or histology. This is 
associated with a potential false positive diagnosis and 
does not allow HPV type to be determined. It is known 
that in many cases cervical infection with HPV is not 
associated with histological evidence of koilocytosis.
Many of the defects in the studies so far discussed 
were resolved in the study reported by Alloub et al (17). 
In this study 49 patients with renal allografts and 69 
non-immunosuppressed patients were enrolled and investi­
gated by cytology, colposcopy, and histology for evi­
dence of CIN. Cervical biopsies from these patients were 
also studied by DNA hybridisation for evidence of HPV 
types 6/11 and 16/18. Alloub et al showed that 26 (53%)
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of patients with allografts had cervical abnormalities 
compared with 20 (29%) of the control group patients. CIN 
was found in 24 (49%) of the patients with allografts and 
7 (10%) of the controls. Overall HPV DNA detection did 
not differ between the two groups but there was a signif­
icant difference in the rate of detection of HPV types 
16/18 (27% in the patients with allografts and 6% in the 
controls). This study resolved many of the problems 
associated with those studies described above. It still 
however, left unquantified the degree of immunosuppres­
sion in the study group and the time span from commencing 
immunosuppressive therapy to enrollment in the study. 
These factors might be expected to influence the inci­
dence and degree of CIN. The control group were well 
selected for those risk factors known to be associated 
with CIN, however a degree of bias in patient selection 
may have occurred, since for the controls to be eligible 
they must have had normal cervical cytology within the 
last two years. Unlike the immunosuppressed patients the 
controls did not have cervical cytology performed and 
this removed a further area of comparison between the two 
groups.
An association has also been noted between immunosup­
pression, HPV and other tumours. A number of case re­
ports exist with reference to bladder neoplasia (19, 20, 
21). Querci della Rovere et al (22) and Benoit et al (23) 
both reported single cases where bladder tumours had 
developed post renal transplantation and using DNA-DNA 
hybridisation had shown the presence of HPV 11. Neither 
case study states whether the presence of any other HPV
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types was considered.
Kitamura et al (24) analysed 10 bladder tumours for 
the presence of HPV DNA. HPV 16 was found in one patient 
who was mildly immunosuppressed and also had VAIN 3, 
Bowen's disease of the vulva, common warts on the hand 
and a recent past history of bladder tumour. Immunosup­
pression in this patient was defined by a variety of 
laboratory tests, none of which were apparently performed 
on the remaining nine patients. Laboratory analysis was 
performed for HPV types 1, 2, 6, 11, 16, and 18 on all 
specimens. The failure to quantify immunosuppression in 
all patients however made it difficult in this small 
study to ascertain whether immunosuppression and/or HPV 
had contributed to the presence of neoplasia.
Following the report by Tay et al (25) that the T4 /T8 
ratio in the cervical epithelium of women with CIN was 
abnormal, Turner et al (26) examined T lymphocytes in the 
peripheral blood of 16 patients with CIN. Nine of the 16 
patients had less than 40% T4 lymphocyte counts and the 
T4 : T8 ratio was inverted in 7 (44%). The authors con­
cluded that CIN was associated with abnormal T lymphocyte 
populations in peripheral blood. Their failure to enrol a 
control group made interpretation of the results diffi­
cult. Factors predisposing to the development of CIN may 
have caused these T lymphocyte abnormalities, eg. smoking 
(27), potentially oncogenic viruses or the immunosuppres­
sive effects of seminal plasma (28).
Conclusion
The above studies all tended to suggest a correlation
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between immunosuppression and tumours. The explanation as 
to why tumours are more likely to occur in immunosup- 
pressed patients is not entirely clear but it would 
appear that the immunosuppressed patient may have a 
defect in immune surveillance (29) or may have in­
creased susceptibility to infection with oncogenic vi­
ruses (13).
Quantification of immunosuppression is difficult and 
care needs to be taken in interpreting results of labora­
tory markers of immunosuppression.
(iv) HIV and immunosuppression.
In 1981, five cases of Pneumocystis carinii pneumonia 
(PCP) occurring in previously healthy homosexual men from 
the Los Angeles area were reported to the Centre for 
Communicable Diseases (CDC), Atlanta, Georgia, USA in 
their weekly report (30). Shortly thereafter, reports 
from New York detailed homosexuals with PCP and KS (31). 
These reports suggested an underlying defect in cell 
mediated immunity and the condition was termed Acquired 
Immune Deficiency Syndrome (AIDS). Initially the only 
apparent risk factor linking these cases was homosexual 
lifestyle. However, over the subsequent two years similar 
cases were recognised amongst intravenous drug addicts 
(32), blood transfusion recipients (33), haemophiliacs 
(34) , heterosexual contacts (35) and children of infect­
ed parents were shown to be at risk over the following 
two years. By 1986 it was apparent that the disease was 
epidemic in Central African countries (36). Epidemiologi­
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cal studies in Africa and on a more limited basis in 
Western countries showed that AIDS was not confined to 
the above risk groups (36, 37). (For further details of 
the mode of HIV transmission see appendix 1.)
In 1983 the causative virus was first isolated in 
Paris from a patient with lymphadenopathy and was termed 
Lymphadenopathy Associated Virus (LAV) (38). These obser­
vations were confirmed and extended both in France and in 
the USA where the virus was named Human T-Lymphotrophic 
Virus Type 111 (HTLV3) (39). Compromise was reached on
the name for the virus with Human Immunodeficiency Virus 
(HIV). There were few cases of AIDS in the UK before 1983 
but by end of January 1989 there were 2049 cases diag­
nosed in the UK (40).
HIV is a retrovirus and as such possesses the enzyme 
reverse transcriptase which enables it to synthesise a 
DNA copy of its RNA genome within the infected host cell. 
This DNA is then "spliced" into host DNA as provirus, 
giving rise to viral latency. New virions are produced by 
budding from the cell surface, a process which occurs at 
low baseline levels during viral latency but which is 
greatly accelerated by activation of infected cells (41).
HIV bears a close genetic resemblance to animal 
lentiretroviruses such as visna virus (42) although 
important differences exist.
HIV is tropic for cells bearing CD4 antigen and demon­
strates a cytopathic effect in cell culture (43). Cells 
which express CD4 antigen on their surface include 
"helper" (T4) lymphocytes , monocytes, macrophages and 
related (immunocompetent) cells including Langerhans1
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cells. Glial and oligodendrititic cells within the CNS 
also express this antigen and are therefore susceptible 
to infection with HIV (44). Under certain circumstances, 
for instance following EBV infection, B cells may also 
express CD4 (45). Recently cell entry independent of CD4 
has been demonstrated (46).
Cellular immunity
In HIV infected patients the characteristic immunolog­
ical abnormality is a depletion of CD4 lymphocytes. This 
occurs as a result of the cytopathic effect of HIV either 
directly, by lysis, or indirectly by syncytial formation. 
In addition, HIV infected CD4 positive cells are targeted 
for elimination by the host immune system, which exhibits 
both cytotoxic and suppressive cellular immune responses 
(44). It has been demonstrated that T8 lymphocytes have 
cytotoxic activity against virus-infected cells in cul­
ture (47). This may have relevance in maintaining the 
antiviral state in the host. There is also evidence that 
T8 lymphocytes suppress viral replication without killing 
the infected cell (48).
Humoral immunity
The humoral response to HIV infection may lead to produc­
tion of autoantibodies. This is compounded by HIV anti­
gens exhibiting homology with portions of normal cellular 
components or products. A potential contributing factor 
to loss of T4 lymphocytes therefore, is the presence of 
antilymphocyte autoantibodies found in the serum of HIV 
infected patients. Infection of other CD4 positive cells
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is enhanced by HIV stimulated non neutralising antibody 
formation and this may contribute to its pathogenicity 
(46).
In contrast to the above negative effects of the 
humoral response, HIV infection can lead to the produc­
tion of neutralising antibodies which may help to prevent 
viral transfer within the host. Antibodies may also 
facilitate elimination of infected cells by antibody 
dependent cellular cytotoxicity (46).
Other immunological responses associated with HIV 
infection are shown in the table below (43, 46, 49):
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Table A 
Cellular immunity 
T lymphocyte depletion (especially T4 cells) 
Abnormal in vitro assays of T lymphocyte function 
Defective natural killer cell function 
Defective monocyte function 
Antiviral suppressor cell response 
Autoimmune cellular responses
Humoral immunity
Non specific B lymphocyte activation with polyclonal 
hypergammaglobulinaemia
Impaired response of B lymphocytes to new antigens 
Enhancing antibodies 
Neutralising antibodies 
Autoantibodies
Others
Reduced alpha interferon levels and raised levels of an 
abnormal "acid labile" interferon
Raised interleukin 2 levels and elevated B 2 microglobu­
lin
Many of these immunological abnormalities are secondary 
to the reduced number and impaired function of CD4 posi-
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tive cells whilst others may be a direct result of HIV 
products, or of other concurrent infections.
HIV related disease is diagnosed on clinical grounds, 
but immunological factors may be of assistance in plot­
ting disease progression.
The spectrum of HIV disease has been classified by 
various methods since the condition was first described. 
The classification advocated by the CDC originally in 
1982, and later updated (50, 51) has proved broadly 
valid (52), is easily workable by large numbers of physi­
cians working in diverse settings and has reasonable 
prognostic significance.
Table B shows the CDC classification (53).
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Table B
Stage 1 Acute infection 
Stage 2 Asymptomatic infection
Stage 3 Persistent generalised lymphadenopathy 
Stage 4 Other disease
A Constitutional disease 
B Neurological disease 
C Secondary infectious disease
Category Cl- Specified secondary infections 
listed in the CDC criteria for AIDS.
Category C2- Other specified secondary infec­
tions, diseases 
D Secondary cancers 
E Other conditions
Stage 1; acute infection
The majority of patients are symptom-free, however in 
approximately 10% of cases an acute glandular fever like 
illness may ensue, with tender lymphadenopathy, fever, 
arthropathy, macular-papular rash, headaches and occa­
sionally aseptic meningitis. These symptoms and signs 
will occur in the first few weeks after infection and 
where present are probably features of viraemia. The HIV 
antibody test described below (pages 82-83) usually 
becomes positive within 1-3 months of infection or in the 
latter stages of the infectious mononucleosis like ill­
ness described above. After initial infection, patients 
either become asymptomatic or develop persistent genera­
lised lymphadenopathy (PGL).
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Stage 2: Asymptomatic infection
During the asymptomatic phase progressive subclinical 
damage is occurring to the immune system. This period is 
of variable length, ranging from months to years and is 
usually associated with HIV antibody seropositivity.
Stage 3; Persistent generalised lymphadenopathy
PGL is defined by the presence of enlarged lymph nodes 
(greater than 1 cm) in two or more extra-inguinal sites, 
persisting for more than 3 months, in the absence of any 
other recognised cause. Nodal size tends to fluctuate in 
response to intercurrent events such as infection and 
fatigue. The nodes are usually firm, non tender, mobile 
and symmetrical, and may include epitrochlear, axillary, 
supraclavicular, cervical, pre-auricular, intra-abdominal 
and inguinal nodes. PGL alone does not indicate poor 
prognosis and patients may remain well for long periods 
of time. Progression rates from CDC 2 and 3 to CDC 4 are 
51% in 10 years (54).
Stage 4j_ (ARC and AIDS)
ARC: A prodromal syndrome for AIDS (Group IV A, C2 and 
E) consisting of greater than 10% weight loss, persistent 
diarrhoea, fevers, night sweats and oral candidiasis was 
first described in 1984 (55). Other prodromal features
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include hairy oral leukoplakia, seborrhoeic dermatitis, 
shingles, recurrent pyogenic infection of the respiratory 
tract or skin, retinal cotton wool spots and moderately 
severe haematological abnormalities including thrombocy­
topenia. ARC progresses to AIDS in 25-70% of cases within 
2 years.
AIDS: These patients have severe opportunistic infec­
tions (Group4 C 1) or opportunistic tumours (Group D) 
indicative of a profound defect in cellular immunity, 
where other causes of such immunosuppression have been 
excluded. The type of opportunistic infection a patient 
develops depends to an extent on his/her environment. In 
the USA the commonest opportunistic infection seen in 
AIDS patients is PCP, whereas in Sub-Saharan Africa, 
tuberculosis is the most significant pathogen in this 
group. The opportunistic tumours most commonly seen in 
AIDS are B cell non-Hodgkins lymphomas and Kaposi's 
sarcoma. Certain opportunistic infections and tumours 
carry a better prognosis than others. Patients with an 
AIDS diagnosis currently may survive for several years 
before succumbing usually to a variety of opportunistic 
infections and/or tumours. The range of tumours include 
B cell and Hodgkin's lymphomas, and Kaposi's sarcoma.
The psychiatric manifestations of HIV disease in women 
are discussed in appendix 3.
(v) Laboratory markers of HIV infection and immunosup­
pression
A number of immuno-assays are available which detect 
antibodies to virus proteins associated with the core and
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envelope of the mature virion. These include the screen­
ing ELISA based systems, which may be direct (eg Abbott, 
Organon) or competitive (Wellcome) in type. Antibody is 
usually detected by 12 weeks following infection, al­
though in some individuals detection may take longer. 
The presence of antibodies does not appear to play a 
major role in virus elimination or protection of the 
individual from disease, but merely serves as a marker of 
prior infection. Antibody detection is widely used as a 
surrogate test for the virus which is both difficult and 
expensive to detect directly by culture. HIV is a life 
long infection and antibody positive individuals must be 
assumed to be infectious by the known routes described 
above. Further details of the tests performed are de­
scribed on pages 82-83.
As knowledge of HIV disease increased, it became 
clear that AIDS, as described above, was the end stage of 
a disease continuum which was largely asymptomatic. This 
stimulated interest in finding laboratory investigations 
which could be used to ascertain the stage of HIV dis­
ease, in order to facilitate appropriate patient counsel­
ling and to enable anti retroviral therapy to be com­
menced at a suitable juncture. To this end, the following 
'surrogate markers' of HIV disease are now used.
T4 lymphocyte counts 
The predictive value of T4 lymphocyte counts in HIV 
disease was calculated in American homosexual men over a 
3 year study period (56). In this study, Moss et. al 
showed that T4 counts decline in HIV seropositive men by 
a mean of 60-100 x 1000/litre a year from a normal value
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of 800-900 x 1000/litre. In the first few years after 
infection most men are asymptomatic and have counts of T4 
cells greater than 400 x 1000/ litre. In 3 years approxi­
mately 14% of men will progress to AIDS. Ninety percent 
of symptomatic men with fewer than 400 x 1000 lymphocytes 
/litre progress to AIDS. The critical number of CD4 cells 
that identify individuals at risk of developing an AIDS 
defining event is 200 x 1000 /litre (57). T4 counts are, 
however, variable and wide individual differences may 
occur making them, in isolation, potentially unreliable 
prognostic indicators for the individual patient.
The above figures are derived from men and are there­
fore not necessarily always applicable to women. It is 
known that pregnancy in the HIV seronegative patient is 
immunosuppressive and that cell mediated immunity, as 
measured by T4 counts is decreased in these individuals. 
However, this decrease is temporary and reverses in the 
postnatal period (58). Whilst pregnancy has not been 
shown to worsen clinical HIV disease in those patients 
who are CDC stages 2 and 3 at the time of becoming preg­
nant (59), T4 counts are reduced in pregnancy and this 
reduction is maintained post delivery in contrast to the 
recovery seen in an HIV seronegative control group (60). 
The long term significance of this remains unclear, but 
it is possible that increasing parity in the presence of 
HIV infection may have a cumulative adverse effect on 
cell mediated immunity.
Virological markers
The p 24 antigen of HIV is a virological marker of pro­
gressive disease. It is first detectable at the time of
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acute infection and thereafter falls with the rise in p 
24 antibody that ensues, usually remaining undetectable 
until late in the HIV disease process (61, 62, 63), 
(Figure 1). Persistent antigenaemia after primary infec­
tion, or the reappearance of antigenaemia later in the 
course of the disease is associated with a poor clinical 
outcome (62). Between 10 and 20% of asymptomatic homosex­
ual men infected with HIV have detectable p 24 antigen on 
ELISA and are at high risk of rapidly progressing to AIDS 
(64). The above data were derived from studies in groups 
of male patients; De Wolf et al and Pederson et al in 
homosexual cohorts (62, 63) and Allain et al in a cohort 
of haemophiliacs (61). No similar data have been compiled 
in a female cohort of significant size. It may not be 
entirely appropriate to extrapolate these findings to the 
female population who have largely acquired their HIV 
infection through heterosexual contact and intravenous 
drug use. In addition pregnancy may influence the detec­
tion of p 24 antigen (65).
A more recent study has compared detection of p 24 
antigen and antibody with frequency of isolation of the 
virus from peripheral blood mononuclear cells (PBMC), and 
cell free plasma in infected individuals (66). In this 
study Coombs et al showed that HIV could be isolated 
from 207 of 213 patients (97%) enrolled, regardless of 
the clinical stage of HIV disease. Plasma viraemia, in 
contrast, corresponded to the clinical stage of HIV 
infection. It was detected in 11 of 48 patients (23%) 
with asymptomatic infection, 32 of 71 patients (45%) with 
CDC stage 4A disease (ARC) and 75 of 92 patients (82%)
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with CDC stage 4C disease (AIDS). Only 45% of patients 
with plasma viraemia had detectable p 24 antigen and no 
correlation was found between the plasma HIV titre and 
the amount of P 24 Ag in the plasma. These results sug­
gest that the capture assay for p 24 antigen is a poor 
predictor of infectious virus. The inability to detect p 
24 antigen in the presence of viraemia may represent the 
sequestration of HIV p 24 into complexes with antibody, 
core antigen, whole virions or each of these. Disease 
does not closely follow the production of, and release of 
HIV core antigen in plasma or serum (66). These authors 
also found that the absence of p 24 antibody was a better 
predictor of HIV disease progression than the presence of 
p 24 A g . They concluded that plasma viraemia can be 
detected at all stages of HIV disease, a finding support­
ed by Ho et al (67). In addition they found that among 
the four virological markers of HIV disease - namely HIV 
p 24 antigen, p 24 antibody, HIV isolation from PBMC and 
isolation of HIV from cell-free plasma - plasma viraemia 
was the best predictor of the clinical stage of HIV 
disease. However the assessment of plasma viraemia is 
both costly and labour intensive, and the results are 
operator dependent; these features make it an impractical 
investigation in many centres.
In conclusion, there appear to be differences in the 
patient populations studied and great heterogeneity in 
the virological course among patients with similar stages 
of HIV disease. Where HIV infected female populations are 
studied the effect of potential hormonal influences may 
need to be considered.
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Beta-2 microglobulin
This small peptide consists of the light chain moiety of 
the major histocompatability complex (HLA) class 1 anti­
gens. Increased production of beta-2 microglobulin (B2M) 
is seen with stimulation of lymphoid cells, particularly 
T cells. Raised serum levels are seen in a number of 
disease states other than HIV infection, including renal 
failure, hepatitis and myeloproliferative disorders. In 
HIV infection, B2M concentration follows a similar pat­
tern to p 24 antigen level, spiking in acute infection, 
declining in the latent phase and rising with progressive 
disease (68). However, unlike p 24 Ag, the concentration 
of B2M is measureable throughout the disease process. 
Elevated levels of B2M have been shown to predict the 
development of AIDS both independently and in conjunction 
with T 4 counts in HIV infected homosexual men. Approxi­
mately 25% of infected men with T 4 counts greater than 
400 x 1000/litre and serum concentrations of B2M greater 
than 3 mg/ml will progress to AIDS over 3 years, whereas 
as many as 75% of men with lower T 4 counts and equiva­
lent concentrations of B2M will progress to AIDS over the 
same period of time (64). It has also been shown to be of 
predictive value in haemophiliacs (69) and female IVDUs 
(70). The upper limit of normal for B2M in blood donors 
and in non HIV infected homosexuals is 1.7 mg/1. This can 
be expected to rise to 5 mg/1 or more with the develop­
ment of AIDS (64).
With the exception of Wallace et al (70) the above 
studies are again based exclusively on men, and therefore
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may not be directly applicable to women. Pregnancy is 
known to increase lymphocyte turnover (71) and therefore 
elevated values of B2M might be expected. Whether B2M 
might continue to be elevated post natally in HIV infect­
ed women is as yet unknown.
Neopterin concentrations
Neopterin is a low molecular weight compound derived 
biosynthetically from guanosine triphosphate. Neopterin 
concentration in urine and in serum has been described as 
a predictor of HIV disease progression independently of 
T4 counts in homosexual men, tending to rise with disease 
progression (72). Facilities were not available for its 
measurement in this study.
Biological properties of HIV variants
Isolates of HIV appear to differ in biological proper­
ties such as replication rate, host range and syncytium- 
inducing capacity. It has been shown that the most rapid 
progression to AIDS is observed in individuals with high 
replicating, syncitium-inducing isolates, whilst individ­
uals with low replicating, non syncitium-forming iso­
lates, have a more indolent pattern of disease (73). In 
addition, cross-sectional studies have shown that the 
prevalence of particular HIV variants differs between the 
early and late stages of infection (74). These findings 
indicate that differences in the biological properties of 
HIV isolates are related to the clinical course of HIV
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disease and may in fact be causal.
Determination of HIV sub-type was not used in our 
study since it is technically difficult and expensive to 
perform, and its exact prognostic significance still 
requires further elucidation.
(vi) The effect of IVDU on HIV disease
Limited information is available regarding the poten­
tial effect of continuing intravenous drug use on HIV 
disease progression. However, in a study of significant 
size, Weber et al showed a relative lack of HIV disease 
progression in a cohort of HIV infected individuals who 
had discontinued their illicit drug use or who had com­
plied with a methadone maintenance programme, in compari­
son with those individuals who had continued using pa­
renteral drugs (75). This was a well designed study, 
which controlled for age, sex and initial T4 count, and 
used a readily quantifiable end point, namely development 
of CDC stage 4 disease. Their data suggests that stopping 
injecting drug use lessens the risk of HIV associated 
morbidity in infected subjects, and are consistent with 
those of Des Jarlais who found that continued drug in­
jecting was associated with an increased loss of CD4 
positive cells in a New York City cohort of HIV infected 
IVDUs (76). No association has been demonstrated between 
the use of non intravenous psychoactive drugs including 
opiates and accelerated immune deficiency in a study of a 
relatively small number of HIV seropositive individuals 
(77).
The deleterious effect of continued illicit parenteral
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drug use is thought to stem from repeated antigenic 
stimulation of HIV infected CD4 cells, which may promote 
HIV expression and viral replication (78). There is howev­
er no evidence in the literature that IVDU in the absence 
of HIV infection predisposes to immunosuppression. The 
only studies suggesting this were performed prior to 
ready availability of HIV testing (79) and the results 
are therefore uninterpretable.
(vii) The effect of zidovudine on HIV disease and immuno­
suppression
Azidothymidine (Zidovudine, AZT) is a thymidine analogue 
that inhibits HIV replication. It is phosphorylated by 
cellular enzymes and in this active form, inhibits re­
verse transcriptase and terminates viral DNA production. 
Zidovudine, at a dose of 250 mgs four times daily was 
shown by Fischl et al (80) to decrease both the frequen­
cy and the severity of opportunistic infections and the 
mortality in those individuals with advanced ARC or AIDS, 
when compared to a similar group of patients given place­
bo. This benefit was shown to last well beyond the study 
period, but was not indefinite (81).
Since then, the use of zidovudine in prolonging the 
asymptomatic phase of HIV disease has been much studied 
both in the UK and France (Concorde trial) and in the USA 
where the first results were published by Volberding et 
al (82). In this study, 1338 male patients with CD4 
counts of less than 500 x 1000 per litre were randomised 
fairly equally into three treatment arms: placebo, 500 mg 
zidovudine per day, and 1.5 G per day. After 55 weeks, 33 
of the subjects assigned to placebo had developed AIDS,
40
as compared to 11 of those assigned to receive 500 mg of 
zidovudine and 14 of those assigned to receive 1.5 G 
zidovudine. In the 3 treatment groups the rates of pro­
gression ( per 100 man-years) were 7.6, 3.6, and 4.3 
respectively. The patients assigned to receive zidovudine 
had a significant increase in the number of T4 cells and 
a significant decrease in the levels of p 24 Ag. In those 
patients receiving 1.5 G zidovudine haematological 
(anaemia or neutopenia) toxicity was more frequent than 
in the other two groups. The authors concluded that 
zidovudine in a daily dose of 500 mg was a safe and 
effective treatment for those patients asymptomatic for 
HIV disease and with a T4 count less than 500 x 1000/1. 
The long term benefits of a strategy of early interven­
tion to delay progression and to prolong survival are not 
yet known. The development of in vitro viral resistance 
to zidovudine, a feature related to duration of therapy 
also merits consideration, although its clinical rele­
vance has not yet been established (83). However, the 
consensus in the USA was that these results merited the 
prescribing of zidovudine to asymptomatic patients with 
reduced T4 cell number (83).
The UK interpretation was a more cautious one, since 
these results showed that zidovudine therapy produced o 
nly a 5% improvement in outcome, as measured by progres­
sion to AIDS, over a period of 1 year. The long term 
toxicity of zidovudine is unknown, and the finacial cost 
of lifelong therapy is high. The effects of long term 
zidovudine in women are unknown, but Wellcome laborato­
ries have described vaginal carcinoma occurring in rats
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on long term therapy (personal communication: Wellcome 
laboratories); the mechanism for this is not understood. 
The potential effects of this drug on pregnancy have 
not been elucidated.
(viii) Local cervical immunity, CIN and HIV 
Langerhans1 cells are epithelial dendritic cells that 
originate from bone marrow (84) and are important in 
presenting antigen to T lymphocytes (85). Their numbers 
in cervical epithelium have been shown to be decreased in 
the presence of HPV infection and in those individuals 
who smoke (86, 87, 92).
Hawthorn et al (86) showed decreased Langerhans1 cells 
associated with moderate to high copy numbers of HPV 16 
and with low copy numbers of HPV 18. In this study, 
increased numbers of Langerhans' cells were seen in 
patients with CIN in the absence of HPV. However, T6 
antigen alone was used to identify Langerhans1 cells, and 
no attempt was made to control for smoking. HPV analysis 
was undertaken on colposcopically abnormal tissue, where­
as biopsies taken from colposcopically normal tissue to 
act as an internal control for Langerhans1 cells analysis 
were not analysed for HPV. In other words the same analy­
ses were not performed in the study and control groups, 
thus calling into question the validity of the conclu­
sions drawn.
Early studies suggested that in the presence of CIN, 
Langerhans1 cells were increased (88, 89) but more recent 
work suggests the opposite (87). The more recent results 
were obtained using two Langerhans1 cell markers S 100
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(90) and common thymocyte antigen, T 6 (CD1) (91).
Smoking has also been shown to influence Langerhans1 
cell number and there was a failure to control for this 
in earlier studies. Barton et_ al^  showed that smoking 
produces a significant decrease in Langerhans1 cells in 
both normal and neoplastic cervical epithelium, whilst 
cervical tissue from ex-smokers tends to have intermedi­
ate Langerhans' cell counts between that seen in smokers 
and non smokers (92). These authors also showed a sig­
nificant decrease in Langerhans1 cells in cervical tissue 
from patients with coexistent HPV and CIN. In this study 
colposcopically directed punch biopsies were taken from 
abnormal tissue and in the absence of abnormality, from 
the transformation zone. Their failure in the presence of 
abnormal epithelium to take biopsies from normal tissue 
meant the study lacked any form of internal control 
group. In addition, HPV infection was diagnosed on the 
basis of histological criteria alone, a technique known 
for its lack of sensitivity and specificity. These criti­
cisms do not however, invalidate the main findings of the 
study which were related to the influence of smoking on 
Langerhans1 cell number.
HIV infection also exerts an effect on Langerhans1 
cell number. The concentration of Langerhans1 cells was 
found to be reduced in skin biopsies from patients with 
both asymptomatic infection and AIDS (93). This reduction 
was more pronounced with progression of disease from ARC 
to AIDS (94). These studies utilised only one monoclonal 
antibody to identify Langerhans1 cells, namely the thymo­
cyte marker T6 (CD1). In only one study was additional
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staining of the S100 protein used, and these authors 
reported weaker staining of Langerhans1 cells in skin 
biopsies from patients with Kaposis1 sarcoma when com­
pared with results seen in tissue from HIV seropositive 
controls not suffering from Kaposis1 sarcoma (95).
Daniels et al (96) examined Langerhans' cell number in 
biopsies taken from areas of oral hairy leukoplakia, an 
EBV associated condition, seen in patients with advanced 
HIV disease. They found that in the 23 HIV infected 
homosexual men studied there was a significant reduction 
or absence of Langerhans1 cells within the lesions in 
comparison to autologous non lesional mucosa.
Conclusion
These authors postulated that a reduction of Langer­
hans ' cells in oral mucosa, occurring as a result of 
advancing HIV disease, may result in local immunosuppres­
sion permitting EBV replication to continue unchecked. A 
similar effect might be found in the cervical epithelium 
of HIV seropositive women and this could contribute to a 
higher incidence of CIN in these women. However, no data 
exists to support this hypothesis.
(ix) Lower genital tract neoplasia and HPV
(a) Lower genital tract neoplasia: cytology, colposcopy
and biopsy.
The lower genital tract comprises the uterine cervix, 
vagina and vulva, all of which have the capacity to 
undergo neoplastic change. At each site, there is a well 
described premalignant stage, that of intra-epithelial
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neoplasia.
Uterine cervix
Pre-malignancy in the cervix was first described by Sir 
John Williams in 1886 when 8 cases of cervical cancer 
were presented, one of which today would be described as 
CIN 3 (97). Rubin in 1910 (98) went on to summarise cur­
rent feeling at that time by stating that pathological 
examination of the uterus could reveal evidence of latent 
carcinoma and that diagnosis of pre-invasive cervical 
carcinoma was possible. He went on to state that the 
ability to differentiate between metaplastic, non- 
malignant epithelial change and atypical epithelium with 
the capacity for future malignancy would determine the 
future ability to improve prophylaxis for invasive cervi­
cal carcinoma (98). At this time it was accepted that 
treatment in the pre-malignant phase was likely to pro­
duce improved results over treatment of overt malignancy. 
There was, however, no method except chance of detecting 
premalignancy until 1925, when Hinselmann described the
i
earliest colposcope and with which he hoped to detect the 
cancer in its earliest stages, as either a small ulcer or 
a small exophytic lesion invisible to the naked eye
(99).
In 1929, Schiller (100) described the iodine test 
subsequently named after him. He had noted that malignant 
squamous epithelium like columnar epithelium and unlike 
normal squamous epithelium, did not contain glycogen. He 
also noted that the presence of glycogen affected the 
ability of the epithelium to stain with a solution of 
iodine, and went on to recommend that those areas failing
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to stain with iodine should be carefully scraped to allow 
detection of potentially abnormal epithelium by cytology
(100). it was not until 1943, however, that large scale 
screening of the population for cervical premalignancy 
became feasible, with the development of the technique of 
exfoliative cytology by Papanicolaou and Traut (101).
Many countries now undertake routine screening of 
their female populations by cervical cytology. The pur­
pose of the cervical screening programme is to reduce 
the incidence of invasive cervical cancer within a speci­
fied population (102). Judged on this criterium, the 
success of cervical screening programmes has varied 
considerably between geographical areas. Finland has one 
of the most successful programmes, as declining incidence 
of mortality from cervical carcinoma has been seen since 
the instigation of cervical cytological screening in the 
early sixties (103). Smear reports differ between cytolo­
gy laboratories, however all cytological findings are 
graded in terms of normal, koilocytosis and/or dyskaryo- 
sis (mild, moderate or severe).
After obtaining an abnormal smear, routine management 
in the UK is to examine the patient colposcopically and 
take punch biopsies under direct vision for histological 
analysis.
The histological terminology for squamous intraepithe- 
lial lesions of the female genital tract:
CIN 1 = mild to moderate dysplasia 
CIN 2 = moderate dysplasia
CIN 3 = severe dysplasia and carcinoma in situ
Gradation of dysplasia is according to the degree of
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cellular atypia and change in epithelial architecture: 
Mild dysplasia - loss of polarity and of regular strati­
fication are minimal. The nuclei are always enlarged, are 
often irregular, and are darkly stained. Mitoses are 
often found and are occasionally abnormal; they are 
confined to the lower third of the epithelium. The cyto­
plasm is generally well preserved and keratinisation of 
single cells of the epithelial surface is a common fea­
ture .
Moderate dysplasia- the degree of epithelial abnormality 
is intermediate between mild and severe dysplasia.
Severe dysplasia- atypia is very pronounced. There is 
loss of polarity and the crowded cells have large, darkly 
stained nuclei. Mitoses, occasionally including atypical 
forms, are seen. The abnormal cells tend to be present in 
the upper third, as well as the middle and lower thirds, 
of the epithelium. The superficial cells show a degree of 
maturation. A layer of flattened cells may form the 
surface. At its most severe the whole lesion shows the 
cellular features of carcinoma, but with no invasion of 
the underlying stroma. This used to be referred to as 
carcinoma in situ.
Invasive cervical carcinoma- stromal invasion has oc­
curred (104).
Histological grading of CIN lesions is subjective, 
as demonstrated by Ismail et al (105) who showed a poor 
level of concordance between histopathologists in diag­
nosing CIN 1 and 2. The diagnosis of CIN 3 and invasion 
was, however, much more reliable.
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HPV and CIN
General
Papilloma viruses are DNA viruses which belong to subgroup 
A of the family of papovaviruses. There are still many 
gaps in our knowledge about the life cycle of the HPV. 
This virus only fully replicates within terminally dif­
ferentiated keratinocytes of the host epithelium, and 
there is no standard tissue culture system available to 
study the virus in vitro. Restriction endonuclease analy­
sis has been used to map genomically distinct types of 
HPV. More than 60 have currently been identified,and 
certain types may correlate with infection at different 
clinical sites and different oncogenic potential (103, 
106, 107, 108, 109). HPV types 6 and 11 have been associ­
ated with genital warts (103), type 10 with flat lesions 
of the uterine cervix (103), and types 16 and 18 have 
been found in association with cancers of the cervix, 
vulva, vagina and penis, and in cell lines derived from 
cervical cancers. HPV 16 and 18 DNA sequences are usual­
ly detected as non-integrated episomal DNA in non-malig- 
nant lesions, however they have been shown to be inte­
grated within the host cell genome of malignant tumours
(107).
Epidemiological evidence:
It is known that, independently of her age, a woman's 
risk of cervical cancer is strongly associated with 
indices of sexual activity such as age at first sexual 
intercourse, and number of sexual partners (110, 111).
There also appears to be an increased risk if the woman's
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partner has himself had multiple sexual partners. In 
addition, it is also known from epidemiological studies 
that smoking predisposes towards CIN (112) and there has 
been much speculation that the oral contraceptive pill 
might be implicated (113). Viruses have also been impli­
cated. HSV has been studied extensively and its role has 
never been conclusively confirmed (114) or refuted (115). 
The potential role EBV is discussed on pages 64-66.
In 1974 the hypothesis arose that certain HPV subtypes 
may play a key role in the development of CIN, and since 
then, much experimental work has emerged to substantiate 
this view. In the 1980's, HPV emerged as the prime candi­
date amongst sexually transmitted agents in the aetiology 
of cervical cancer. The favourite current hypothesis is 
that certain types of HPV play a key aetiological role
(108). This hypothesis emerged in the 1970's (109). Since 
then much experimental work has emerged to substantiate 
it (108, 109). However the epidemiological evidence is 
more difficult to assess due to problems in determining 
prior HPV exposure. No reliable serological test for its 
antigens exists, nor is it possible to culture HPV in 
vitro.
Assessment of HPV infection has therefore been based 
on different criteria in different studies. Clinical 
examination, colposcopy, cytology, and histopathology 
have all been used as diagnostic methods for HPV. Cloning 
of HPV-DNA in bacteria and the application of DNA hybrid­
isation methods revealed the large variety of HPV types 
and is useful as a means of assessing type specific 
infection. The DNA amplification technique of PCR pro­
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vides the most sensitive method of viral detection.
Doubt has been cast on the role of HPV 16 and 18 since 
these viruses have been commonly found in normal cervical 
tissue (116, 117). In the case of HPV 16, Meanwell et al 
(118) showed that after age adjustment the relationship 
between HPV 16 and cervical neoplasia disappeared. Fur­
ther doubt exists since the prevalence of HPV 16 has 
varied from 18-92% in studies of cervical cancer biopsy 
specimens and 0-34.6% in studies of normal cervical 
epithelium (119). These prevalence rates became even 
higher when studies using PCR to detect cervical infec­
tion with HPV 16 and 18 were referenced. This will be 
discussed below.
Epidemiological studies fall into two categories, 
prevalence and cohort studies:
(c) Prevalence studies
A large number of studies have been performed in which 
the prevalence of cervical infection with HPV 6, 11, 16, 
and 18 have been determined by DNA hybridisation tech­
niques. The patients were classified into 2 categories: 
normal, and invasive cervical cancer (118), and in 3 of 
the studies referenced, CIN including gradation was 
differentiated (117, 120, 121). The initial impression on 
studying these reports is that HPV 16 and 18 were more 
prevalent in CIN lesions than they were in normal cervi­
cal epithelium and that HPV 6 and 11 were uncommon in 
invasive cervical lesions but more common in CIN lesions 
than in normal cervical epithelium.
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In all the reports cited above control groups were 
used, however, the selection of these may have introduced 
an element of bias. In every case the control groups 
were much smaller than the study groups. Ideally the 
controls should have been selected to match the study 
group for risk factors for CIN. Controls should have 
been taken from a population representative of that from 
which the cases were derived, preferably by case matching 
the controls for CIN risk factors. In a case control 
study, a control should be defined by the absence of the 
disease which defines the case, regardless of the 
presence or absence of the exposure under study, in this 
case HPV (122).
Problems also exist as described previously in cyto- 
logical and histological grading of CIN (105). This was 
particularly marked in low grade lesions, where the 
difference between CIN 1 and evidence of HPV infection as 
detected by koilocytosis may have been small, thus caus­
ing some HPV lesions to be classified as CIN. This could 
have led to an increase in the reported incidence of HPV 
types detected in CIN lesions. The selection of controls 
could have been biased by the exclusion of those individ­
uals with abnormal cytology, since this inevitably would 
have excluded many of those with HPV infection.
Cervical sampling methods were also different between 
patients and controls. Patients with cervical neoplasia 
had biopsies performed whilst the controls underwent 
cervical cytology alone. Biopsies were taken from colpo- 
scopically abnormal areas, whereas cytology potentially 
sampled the entire cervix. The problem of false negative
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smears is also well recognised and is related to the 
proportion of the transformation zone which is abnormal. 
In those women with small areas of abnormality the chance 
of a false negative smear is increased (123). No compari­
son has been made between the efficacy of DNA hybridisa­
tion using the 2 sampling methods and, therefore the 
effects of the above discrepancies remain unknown.
Crum et al (124) studied two groups, one with CIN and 
the other with condylomata. They used Southern blot hy 
bridisation and DNA in situ hybridisation to detect HPV 
sequences and compare the epithelial distribution of HPV 
16, and 6/11 in CIN and selected condylomata. HPV 16 was 
found primarily in areas of CIN which contained either 
maturation or koilocytotic atypia. Some differences in 
patterns of hybridisation for HPV between CIN and condy­
lomata may be explained by morphologic differences in the 
2 classes of lesions. This study is flawed by the lack of 
a control group with normal histology.
DNA hybridisation was performed by three techniques 
in the above studies (117, 118, 120, 121, 124): dot-blot, 
Southern blot, and in. situ hybridisation. Dot-blot 
analysis is performed by extraction of cellular DNA 
followed by the application of hybridisation probes to 
the unseparated DNA samples. This technique does not 
allow assessment of HPV integration. Southern blotting 
involves hybridisation of radiolabelled cloned HPV DNA to 
cellular DNA extracts, which have been cut and separated 
by gel electrophoresis; this is more specific than dot- 
blot analysis. In iri situ hybridisation, DNA is not 
extracted, but the probes are applied directly onto
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fixed tissue (in situ) or to cells which have been fil­
tered onto nitrocellulose gel (filter in situ). None of 
these 3 methods had been evaluated against each other, 
making direct comparison between studies difficult. It is 
also apparent that the sensitivity and specificity varies 
depending on whether the tissue is neoplastic or normal. 
Southern blot and dot-blot analysis, which involve DNA 
extraction, are more sensitive in the presence of the low 
viral copy number seen in malignant tissue. The in situ 
methods are more sensitive when the copy number is high 
in relatively few cells, as is found in condylomata or 
normal cervices (117, 118, 120, 121, 124)
Statistical analysis was confounded by failure to 
select appropriate control groups. Of the studies cited, 
the only one which controlled for age was that by Mean- 
well et al (118). McCance et al (120) documented the 
ages of their study and control groups, however, the 
others did not.
More recently the polymerase chain reaction has been 
used to determine the prevalence of HPV (125, 126, 127). 
Young et al_ (125), reported a study of 38 women with 
cytological abnormality all of whom were positive for 
cervical HPV infection using PCR analysis. In thirty two 
of these HPV 16 was detected and in 22 of these, HPV 11 
was also found. In seven of the 10 women enrolled with no 
cytological abnormality, cervical infection with HPV 16 
or 11 was detected using this technique. The PCR method 
employs a primer directed, enzymatic amplification of 
specific target DNA sequences (128), and the technique has 
the ability to amplify a specific target sequence present
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only once in a sample of 10,000-100,000 cells. The sensi­
tivity of the technique is many times that of Southern 
blotting (119), in which the detection of less than one 
copy of viral DNA per haploid cell genome is difficult 
(125). However owing to its extreme sensitivity PCR 
analysis may produce false positive results with DNA 
contamination of either the samples or the primers (129). 
The authors point out that careful handling and the 
inclusion of negative control DNA avoids this possibili­
ty.
Subsequently, Tidy et al (126) reported a substan­
tially larger study in which they corroborated the high 
percentage prevalence of HPV 16 in cervical tissue from 
women with normal cervical cytology (84%), normal cytolo­
gy post laser cone biopsy (100%), dyskaryosis (70%) and 
cervical carcinoma (100%).
Syrjanen (103) stated "extreme scepticism should be 
exercised in interpreting the reports of an 80% detection 
rate of HPV 16 DNA in "normal women" (ie those with 
normal cytology)". This scepticism proved to have been 
justified when Tidy and Farrell published a retraction 
(130) of their findings in both "normal" and "abnormal" 
women (131). Reanalysis of 50 of the same specimens with 
normal cytology, again using PCR, revealed that 7 (14%) 
had HPV 16 (personal communication, D Wrede). In the 
light of the above retraction the data of Young et al 
should be treated with caution. Pao et al (127) using 
PCR showed that 43 (42.2%) of 102 patients with normal 
cytology had evidence of HPV DNA in the cervix. No at­
tempt was made to determine HPV type and their findings
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suggest a feasible prevalence rate.
(d) Cohort studies;
In these studies a group of women with cervical abnormal­
ities are enrolled and are then followed up to assess the 
occurrence of advancing cervical lesions and HPV infec­
tion. However, such studies have lacked a control group 
since they do not involve the follow up of women with 
initially normal cytology.
Three studies have assessed HPV exposure on the basis 
of type-specific DNA hybridisation (117, 132, 133).
Campion et al (132) carried out filter DNA hybridisation 
on cytological specimens from women with CIN 1, both at 
initial diagnosis and during follow-up. In 22/26 (85%) of 
cases with progressive disease infection with HPV 16 was 
detected. This study seemed to provide good evidence for 
the involvement of HPV 16. However all the patients 
enrolled were young (under 30) and there was no control 
group of women with normal cervical cytology.
Schneider et al^  (117) followed a group of 36 women 
with a cytological diagnosis of CIN or HPV. Five of the 
24 women in whom only HPV 16/18 was detected progressed 
to CIN 3, as compared with none of the 12 women positive 
for HPV 6/11 alone. In this study, the control group was 
poorly selected.
Syrjanen et al (133) has shown that the progression 
rate of cervical abnormality in his cohort, was higher in 
those women infected with HPV 16/18, than in those with 
HPV 6/11 infection alone. In this study both smears and 
biopsies were taken. It is not known what the effects of
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multiple biopsy are on the natural history of cervical 
HPV infection or neoplasia, however it has been suggested 
that in some cases, cervical biopsy may be therapeutic 
(132).
In conclusion, on the basis of the existing epidemio­
logical studies, the evidence implicating HPV as the 
primary aetiological agent of cervical neoplasia is still 
not conclusive.
(e) Experimental evidence:
In 1933 Shope found evidence of warts in the cotton­
tail rabbit. He demonstrated the infectious nature of 
these warts by infecting domestic rabbits with papilloma 
material from their wild cousins (134). The cottontail 
rabbit papillomavirus is now known as the Shope papilloma 
virus (135). In the same institution, Rous and Beard ob­
served that some of the cottontail rabbits infected with 
papilloma virus developed squamous carcinoma at the same 
site. They also noted that certain chemicals including 
tar and methyl cholanthrene when applied to the papillo­
mata seemed to encourage the development of squamous 
carcinoma (136).
In humans there were isolated reports of malignant 
transformation of condylomata accuminata. However, the 
best evidence of malignant potential in condylomata 
accuminata came from a rare condition, epidermodysplasia 
verruciformis (EV), which was described in 1922 by Lewan- 
dowski and Lutz. In this condition, a defect in cell 
mediated immunity renders the affected patient incapable 
of mounting an adequate response to infection with HPV. 
As a consequence of this, patients develop multiple skin
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warts, in which malignant transformation occurs, particu­
larly in those areas exposed to sunlight. This suggests 
that ultraviolet light may act synergistically with HPV 
in the development of malignancy. More recently it was 
noted that bovine papillomavirus (BVP) which is capable 
of transforming cells in vitro appeared to induce fibro­
blastic tumours in horses and hamsters (135). BPV also 
induces alimentary tract papillomata in cows. These had a 
much higher chance of undergoing malignant transformation 
if the cow grazed on bracken fern, possibly by a direct 
effect on the hosts1 immune system (137).
HPV viral DNA is commonly found within biopsy speci­
mens from malignant epithelial tissue. This however, does 
not necessarily imply a causative role, but may merely 
signify a "high affinity" of particular HPV types to 
transformed cells. There is however reasonable evidence 
that the role of HPV is causative rather than coinciden­
tal in established cancer cell lines.
HPV 16 unlike HPV 6 has transforming properties and 
the ability to immortalise primary human keratinocytes in 
vitro (138). The early viral proteins E6 and E7, play a 
major role in the immortalisation of these cells (139, 
140). HPV 6 (141, 142) and 11 (142, 143) are mostly found 
in genital warts, whereas HPV 16 and 18 are associated 
with 70% of cervical cancers (143). If other virus types 
thought to have malignant potential are included (HPV 
types 31, 33, 35 and 39) there is an association in over 
90% of cases (143). The papillomavirus genome is commonly 
found in primary tumours and metastases, and it is also 
found in cell lines derived from biopsies of malignant
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tissue eg HeLa cells (144). These cell lines show a 
persistence of HPV genome over many years even in the 
presence of multiple chromosomal alterations. Under these 
circumstances genes encoding for E6 and E7 regions of the 
HPV genome were consistently conserved.
HPV viral DNA has been shown to be actively tran­
scribed within the cells of malignant epithelial tissue 
(144, 145). Viral DNA replicates and is found in an 
episomal form in benign lesions, but within cancer cells, 
it is covalently linked to cellular DNA sequences (146). 
Integration appears to occur at random and both episomal 
and integrated forms of the complete HPV 16 genome have 
been implicated in cervical tumours (147). It has also 
been demonstrated that the growth efficiency of cancer 
cell lines iri vitro is correlated with the amount of 
early viral protein expressed within the cells (143). 
Whilst HPV appears to play a role in the aetiology of 
cervical cancer, alone it is insufficient to cause the 
malignant transformation of a normal epithelial cell. The 
epidemiological studies described above demonstrate that 
the association is not direct. In addition, it is known 
that malignant tumours are monoclonal and, therefore, 
only one or a few of the many HPV infected cells escape 
the normal cellular control mechanisms resulting in 
malignancy. It appears therefore that cervical onco­
genesis is largely dependent on cofactors. The mode of 
action of these cofactors is currently poorly understood.
Cofactors have been discussed in detail under the 
various sub-headings within the introduction. Their 
relation to HPV will be discussed here with cross refer­
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encing to other parts of the introduction in brackets. 
Smoking is known to be a cofactor and it has been specu­
lated that mutagens in cigarette smoke induce the cellu­
lar repair mechanisms including cleavage and rejoining of 
DNA. It is likely that at the same time recombinational 
events are triggered favouring the integration of foreign 
DNA into the host genome (143, 148). Mutagens may also 
act to inhibit factors which have a down-regulatory 
influence on HPV gene expression (149).
It is known that pregnancy increases the incidence 
and severity of genital warts, probably as result of a 
temporary reduction in cell mediated immunity (as dis­
cussed on page 36). In addition, long term oral contra­
ceptive usage may be a risk factor for cervical cancer, 
by altering hormone status and thus potentially influenc­
ing HPV expression (150, 151). Corticosteroids increase 
expression of HPV 16 and 18 and enhance growth in cell 
lines infected with these HPV types (143).
Conclusion
The outcome of genital HPV infection appears to depend on 
the site of the infected cell, virus type, and immunolog­
ical status of the host, as well as the genetic back­
ground of the host and exposure to cofactors.
There is ample evidence to suggest that latent HPV 
infection occurs although its role in cervical malignancy 
is unknown. The HPV genome often appears to undergo 
transition from free episome in cervical premalignancy to 
an integrated state in invasive disease. It therefore 
seems likely that integration usually precedes malignant
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transformation.
In conclusion the experimental evidence is compelling 
that certain HPV types have oncogenic potential in 
cervical epithelium, but conclusive experimental and 
epidemiological evidence is still lacking.
(x) EBV, CIN, and HIV
EBV is a member of the herpesvirus family, and as such 
once infection has occurred, there is lifelong persist­
ence of the viral genome, resulting in latent infection 
(152). Its role in oncogenesis was first described by 
Burkitt, who demonstrated its close association with a 
lymphoma seen in central African children (153). It was 
later found to be the aetiological agent in the develop­
ment of nasopharyngeal carcinoma, in the Chinese male 
populations of South East Asia (152, 154). Herpesviruses, 
including EBV were also previously implicated in the 
development of AIDS (155, 156). In-vitro data suggests 
that herpesviruses may act as cofactors in HIV pathogen­
esis by transactivation of the HIV genome (157). Attempts 
to investigate this association have been hampered, since 
more than 90% of HIV seronegative men and women worldwide 
(158) and approaching 100% of the HIV seropositive popu­
lation have previously been infected with EBV. Amongst 
HIV seropositive men, investigators have attempted to 
determine whether significant rises in EBV antibody 
titre occur with progression from CDC stages 2 and 3 to 
CDC stage 4 disease (159). However, the polyclonal gam-
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mopathy associated with HIV infection renders these 
results very difficult to interpret (160).
Holmberg et al in his study of 34 patients with 34 
matched controls failed to demonstrate a rise in EBV 
antibody titre with HIV disease progression (159).
EBV has recently been isolated from cervical smears 
and washings (161, 162). Sixbey et al (161) detected EBV 
infection in 5 of 28 (18%) women studied by cytohybridis- 
ation and viral culture techniques. In four of the women, 
cell free EBV was detected and in 2 EBV DNA was detected 
within cervical epithelial cells. Two of the women were 
recovering from infectious mononucleosis and therefore 
cervical excretion might be expected. In the remaining 
patients however, there was no serological evidence of 
acute EBV infection. The detection of EBV within the 
cervix suggests that cervical epithelium is a site for 
viral replication. No cytological or colposcopic examina­
tion of the cervix was carried out in this study, the 
authors did, however, speculate on the oncogenic poten­
tial of EBV at this site.
More recently Bevan et al (162) used PCR to determine 
the incidence of HPV, EBV and HSV viruses in 36 women 
with histologically proven cervical epithelial abnormali­
ty. They demonstrated EBV DNA in 12 women (33%) and 
suggest that further study is merited. This study failed 
to have a control group with normal cervical epithelium 
and no definition was given as to what categorises cervi­
cal epithelial abnormality. A literature search has 
revealed no study comparing rates of EBV DNA detection in 
patients with normal and abnormal cervical epithelium.
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Langerhans1 cells in the human nasopharyngeal epithe­
lium may be infected by EBV. It was postulated that the 
infection of Langerhans' cells by cytolytic viruses 
removed the cellular defences in the epithelium and al­
lowed the epithelial cells to undergo malignant transfor­
mation in response to infection with other viruses (163). 
This process may also occur in the cervix.
The association of EBV with malignancy at other sites 
has been noted, particularly in immunosuppressed patients 
(96). Oral "hairy" leukoplakia (OHL) (as discussed on 
page 33) is a lesion of the intraoral mucosa associated 
with EBV proliferation in immunosuppressed individuals 
(96, 164, 165). EBV has also been demonstrated in epider­
mal skin lesions in a patient immunocompromised as a 
result of chronic lymphocytic leukaemia (166).
A literature search revealed that no studies had been 
performed observing for potential correlation between 
HIV related immunosupression, the permissive replication 
of EBV in the cervix and a potential oncogenic effect.
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Chapter 3 
Methods
(i) Study Design and Patient Recruitment
Prior to commencing the study calculations were per­
formed to ascertain the number of patients that were 
required to be enrolled to give the study a power of 89%. 
These were based on there being a 45% incidence of CIN in 
HIV seropositive women, as derived from the studies 
which had already been published (3, 4, 6). An incidence 
of 10% was assumed for the HIV seronegative patients, as 
derived from a review of the incidence of CIN in women 
attending the Genitourinary medicine department at St. 
Mary's Hospital. Using the above criteria, to obtain a 
power of 89% 40 subjects were required in each group, and 
it was intended to enrol 50.
Forty HIV seropositive patients were enrolled from 
the Department of Genitourinary medicine and the Drug 
Dependency Unit at St. Mary's Hospital, London W 2 . The 
author over the two years that the study was undertaken 
provided a gynaecological and obstetric service for HIV 
seropositive patients in the Parkside Health Authority. 
This was under the supervision of Messrs. P. Mason and A. 
Fraser. In addition, a general gynaecological service, a 
pre and post pregnancy counselling service were provided. 
Facilities were available to offer pregnant patients 
termination of pregnancy or antenatal care depending upon 
patient preference. Patients were recruited from the GUM 
clinic by referral to the author of known HIV seroposi­
tive women for gynaecological and obstetric advice.
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Thereafter patients were with informed consent enrolled 
into the study. Psychologists at the DDU also referred 
patients to the author for medical and gynaecological 
advice which allowed further recruits to the trial. 
Referral of HIV seropositive women was also made by Dr C 
Smith of the Raymede Family Planning Clinic.
A further 10 HIV seropositive patients were enrolled 
from the Unit of Infectious Diseases, Ruchill Hospital, 
Glasgow via the Claremont Terrace family planning clinic. 
These known HIV seropositive patients were referred to 
Dr. M. Hepburn for general gynaecological advice partic­
ularly related to contraception, pre-pregnancy counsel­
ling, and termination of pregnancy. Thereafter, again 
with informed consent, patients were enrolled onto the 
study. All patients enrolled in the study had been tested 
for HIV by enzyme linked immunosorbent assays (ELISA) to 
detect envelope antibodies to HIV 1 and 2 and p 24 anti­
body to HIV 1. In London all the HIV seropositive women 
regularly attending St Mary's Hospital between October 
1988 and November 1990 were enrolled. In Glasgow all the 
HIV seropositive women who attended the Family Planning 
Cinic at Claremont Terrace between February 1989 and 
August 1990 were enrolled, representing approximately 30% 
of the HIV seropositive patients attending Ruchill at 
that time.
The HIV seronegative case matched control group were 
all enrolled via the GUM department at St. Mary's Hospi­
tal. The method of recruitment is described below. The 
HIV seronegative patients had all been tested by the 
method described above for HIV 1 & 2 within the previous
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12 months. They gave no current epidemiological risk 
factors for HIV infection. For ethical reasons HIV 
seronegative control group patients were not retested 
for HIV after enrollment in the study.
The HIV seronegative patients were case matched 
against the HIV seropositive patients for CIN risk fac­
tors, namely age (banded by decade), age of first sexual 
intercourse (banded <16, or >=16), total number of sexual 
partners in a lifetime (banded 1-10, 11-40, >40), and a 
current history of smoking (banded yes/no) (168, 169). It 
had originally been intended to control for nationality, 
drug-use and prostitution as an occupation; these parame­
ters, however proved too difficult to match for.
More than 2500 HIV seronegative patients were inter­
viewed in the search for suitable controls. They were 
taken through the following questionnaire by either the 
author, Ms. C. Wells or M s . M. James: 
date of birth
Have you ever had an HIV test? yes/ no 
If the answer to this question was "no", then no 
further questions were asked and the patient was excluded 
from the trial since it would have been unethical to 
undertake HIV testing purely to allow patient recruit­
ment. If the answer to the above was "yes", as it was in 
approximately 1800 of the questionnaires undertaken, then 
the following questions were asked:
Are you a cigarette smoker? yes/ no. If "yes" how many 
per day?
Age of first sexual intercourse?
Approximate number of sexual partners in your lifetime?
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The patients were then matched individually against their 
HIV seropositive counterpart.
(ii) Data Collection
After the patients had agreed to take part in the 
study they attended the colposcopy clinic at the GUM 
Department. Both HIV seropositive and seronegative pa­
tients were firstly taken through the questionnaire in 
appendix 4 which comprised both clinical history and 
examination. In addition to the questions in the ques­
tionnaire, the date of each patient's first positive HIV 
test was also documented, as was their putative mode of 
transmission and the year this was thought to have 
occurred.
(iii) Clinical Examination
Patients had a full physical examination performed 
to allow staging of HIV disease. This comprised a general 
examination of the mouth for oral hairy leukoplakia, oral 
candidiasis and other pathology. Examination of the skin 
for evidence of rashes: Kaposi's sarcoma and fungal or 
parasitic infection. Lymph nodes were then looked for: 
pre and post auricular, cervical, supra-clavicular, 
axillary, and inguinal. This was followed by a full 
respiratory and cardiovascular system examination. 
Thereafter, abdominal examination was performed and the 
presence of hepatosplenomegaly or abdominal masses noted. 
The central nervous system was examined by assessment of
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the cranial nerves, reflexes, tone, power and sensation. 
Finally if clinically merited the optic fundi were exam­
ined. The results of the above examination were document­
ed in the questionnaire as shown in appendix 4.
(iv) Gynaecological and STD examination : Colposcopy 
Following inspection of the vulva, a urethral swab 
was taken and smeared onto a slide for Gram staining for 
NG, the swab was then directly plated onto Thayer's 
medium. Thereafter a speculum was passed and cervical 
cytology performed using an Aylesbury spatula. The spatu­
la after being smeared on a slide was placed into phos­
phate buffered saline. A second spatula was used to 
obtain a further exfoliative cytological specimen from 
the cervix and this was placed directly into the same 
container. Swabs were then taken from the endocervix for 
Gram stain and culture for NG, a microtrak and ELISA for 
CT and culture for HSV. This was followed by a high 
vaginal wet preparation for CA, TV and GV. Thereafter 
colposcopic examination using 3% acetic acid and Lugol's 
iodine were undertaken. If an abnormality was observed, a 
biopsy was taken and sent for histological analysis.
In the final fourteen HIV seropositive patients 
enrolled a cervical biopsy was taken regardless of per­
ceived abnormality and sent for Langerhan's cells estima­
tion. These biopsies were taken from colposcopically 
abnormal epithelium if any remained after biopsy for 
histology; if not a biopsy was taken from epithelium with 
normal appearance. Colposcopic assessment of the vagina, 
vulva and perianal area was then performed and any abnor­
mal areas visualised were biopsied. If at perianal exami­
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nation the anal margin was
involved proctoscopy was performed. If biopsy was re­
quired from the vagina, vulva or perianal area, it was 
performed under local anaesthetic. Finally a bimanual 
pelvic examination was undertaken to ascertain uterine 
size and position and the presence or absence of adnexal 
pathology.
(v) Cytology and Histology
Cervical cytology specimens obtained in London were 
analysed in the Cytology Department at St. Mary's Hospi­
tal by the same senior cytologist. In Glasgow all speci­
mens were examined by the same senior cytologist in the 
laboratory at Stobhill Hospital. Both centres reported in 
terms of mild dyskaryosis suggestive of CIN 1, moderate 
dyskaryosis suggestive of CIN 2, and severe dyskaryosis 
suggestive of CIN 3. Koilocytotic change was also report­
ed.
Histopathology was performed in the histopathology 
departments of the Samaritan Hospital, London and Stob­
hill Hospital, Glasgow. Specimens were reported in terms 
of CIN1, 2, and 3 respectively. The presence or absence 
of invasion was always documented.
(vi) Haematological Investigations
HIV seropositive patients had venous blood drawn for 
full blood count estimation with a differential white 
count. T4 and T8 counts were also performed and their 
relative ratios calculated. T4/ T8 counts were performed 
by flow cytometry. Flow cytometry is a method of studying
68
cells which can be induced to show fluorescence. The 
commonest method of inducing fluorescence in cells is by 
the use of antibodies to specific cell antigens which 
have been conjugated to fluorescent compounds eg. fluo- 
rescine isothionate (FITC) = green and Phycoerythrin (PE) 
= orange. Using such labelled antibodies it is possible 
to study the percentage of particular lymphocyte subsets 
which are immunologically important. The use of dual 
antibody reagents allows the rapid enumeration of two 
subsets at one time, in this case T4 and T8 cells. Analy­
sis was done on a histogram.
Direct labelling of lymphocytes was performed using 
the following reagents: 1 "Cytostat" antibodies: MsIgGl 
negative control, T11-RD1 B4-FITC, T8-RD1 T4-FITC.
Methods
1. Three tubes were labelled for each patient negative, 
T11/B4 and T4/T8.
2. One hundred ul of well mixed blood was added to each 
tube.
3. Ten ul of appropriate antibody were added to each of 
the 3 tubes.
4. The tubes were then incubated at room temperature 
for 10 minutes.
5. Each tube was then in turn run through the "Q-prep" 
lyse/fix system on a 35 second cycle. The Q-prep is a 
work station that lyses the red blood cells and fixes 
lymphocytes automatically. The active ingredients of the 
Q-prep are: Solution A - Formic acids (lyses red cells).
Solution B - Stabilisers to buffer the system 
(sodium bicarbonate, sodium chloride and sodium
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sulphate).
Solution C - Paraformaldehyde which fixed the
lymphocytes.
6. Test protocols were then selected on profile in the 
following order: Q-prep (neg), T11/B4, then T4/T8.
7. The specimens were then analysed on the profile in 
the order specified above.
Haematological investigations were not performed in HIV 
seronegative control patients.
(vii) Virological Investigation
HPV
Cervical epithelial DNA was extracted from the PBS 
solution into which the Aylesbury spatulae had been 
placed.
DNA isolation from cervical specimens:
(a) Each sample was vortexed and their respective 
Aylesbury spatulae discarded into a Chloros pot using 
forceps. The forceps were then steeped in glutaraldehyde 
for at least 24 hours after use.
(b) Each sample was then spun down at 3000 rpm for 5 
minutes and the supernatant discarded.
(c) The pellet was resuspended in 160 ul of twice con­
centration Summer's buffer, and transfered to a sterile 
screw-cap! Eppendorf centrifuge containing lOOul sterile 
water, 28 ul 2.5% sds, 32 ul 10 mg/ ml Pronase E and 4 ul 
0.8 mg/ ml t-RNA.
(d) This was then incubated overnight at 37 degrees C.
(e) Phenol/ Chloroform extract was produced by adding
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320 mis of TE equilibrated phenol, vortexing it and 
spinning the solution at maximum speed for 10 seconds in 
the Eppendorf centrifuge. The top aqueous phase was 
transferred to a sterile Eppendorf and the process re­
peated. Three hundred and twenty ul 1: 24 isoamyl alcohol 
in chloroform was then added, vortexed and spun for 10 
seconds at top speed in an Eppendorf centrifuge and then 
transferred to a sterile screw top Eppendorf.
(f) Ethanol precipitate was then produced by adding 640 
ul ethanol and 32 ul 5M NaCl. This was then frozen at -70 
degrees C for 1 hour or at -20 degrees C overnight. This 
was then spun down for 10 minutes and the supernatant
taken off, 200 ul of 70% ethanol was then added, vortexed
and spun for 5 minutes. The supernatant was then removed 
and the resulting pellet dried in the vacuum dessicator 
for 1 hour. This was then resuspended in 40 ul sterile 
double distilled water.
Electrophoresis 
Twenty ul of the sample was digested with 20 units (2 
uL) of BamHl for 1 hour at 37 degrees C. It was then run 
overnight on a 1% agarose gel at 14 mAmps ( 7 mAmps if 2 
rows of wells were used). The gel was then stained for 10 
minutes with 160 ul lmg/ml Ethidium Bromide in TAE. It 
was then destained in TAE for 60 minutes. The DNA was 
then broken up in 0.25 M HC1 for 15 minutes. The DNA was
then denatured in 1.5 M NaCl/ 0.5 M NaOH for 30 minutes.
This was thereafter neutralised in 1.5 M NaCl / 0.5 M 
TRIS pH 7.5/ 1 mM EDTA for 60 minutes.
Southern Blotting
The gel former was then upturned in a tray to create a
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bridge. A length of blotting paper was cut as wide as the 
gel and long enough to reach the bottom of the tray at 
both ends in order to act as a wick. Two further pieces 
of blotting paper were also cut to the size of the gel. A 
piece of HyBond membrane was cut to the size of the gel. 
The tray was filled with six times SSC.
The wick was placed on the bridge and soaked in solu­
tion in the tray. Any resultant air bubbles were removed 
with a pipette used in the fashion of a rolling pin. The 
gel was placed on top of the wick and the SSC was pipet­
ted under it to get rid of any air. The membrane was 
carefully positioned and SCC again soaked in. A pipette 
was again used to remove air bubbles. This process was 
repeated with the 2 pieces of blotting paper. Two pack­
ets of medical wipes were placed on top of the blotting 
paper, and topped with a plastic lid. This was compressed 
with a weight of 1-1.5 kg and left overnight. In the 
morning the medical wipes and the blotting paper were 
remove and discarded. The corner of the filter paper was 
cut with a scalpel to allow orientation, washed briefly 
in 2 x SSC to remove traces of agarose, blotted dry and 
placed in an incubator for 30 minutes. When dry it was 
wrapped in cling film and irradiated with ultra violet 
light for 5 minutes to bind the DNA to the membrane.
DNA hybridisation
Hybridisation mixture: 6 x SSC (4.5ml)
5 x Denhard (3.75ml)
0.5% SDS (0.75ml)
1 mM EDTA (30ul)
Standard double distilled water
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Salmon sperm DNA 50 ug/ml (75ul) 
(total=15ml)
Stringent washes: 2 x 10ml 20 x SSC
lml 10% SDS 
89ml water
0.1ml x 0.5 ml 20x SSC 
1 ml 10% SDS 
98.5ml water
The incubator was then warmed to 65 degrees C, as were 
the hybridisation tubes and mixture and the stringent 
washes.
Prehybridisation: The membrane was rolled up and in­
serted into the hybridisation tube, DNA side inwards. The 
hybridisation mixture was added and any large air bubbles 
trapped between the membrane and the glass wall of the 
tube were chased out. The tube was placed in a roller 
inside an incubator preheated to 65 degrees C, and was 
set to rotate for 2 hours. During this time the probe was 
labelled.
Hybridisation: the probe was denatured by adding one 
fifth volume 1 M NaOH, mixing it and leaving it to react 
for 10 minutes. This was followed by neutralisation which 
involved adding one fifth volume 1M Tris at pH 7.5 and 
one fifth volume 1M HC1. The hybridisation mixture was 
then removed and the probe mixed into it and returned to 
the hybridisation tube. The tube was then placed into the 
roller and set to rotate overnight at 65 degrees C.
Stringent washes: The hybridisation mix was then poured 
off and replaced by lOOmls of 2 x wash. It was rotated 
for 60 minutes in a temperature of 65 degrees C.
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It was then replaced by 0.1 x wash and rotated for a 
further hour again in a temperature of 65 degrees C. The 
membrane was removed, patted dry with 3 mm filter paper, 
avoiding complete drying and wrapped in cling film and 
placed in an autoradiography cassette with radiographic 
film (Kodak x-OMAT S) and exposed overnight at -70 de­
grees C. The film was developed and the membrane was 
thereafter exposed for a further five days at -70 degrees 
C.
Washing probe off: The membrane was unwrapped and
incubated in 0.4M NaOH at 45 degrees C for 30 minutes and 
neutralised with 0.1% SDS, 0.1 x SSC, 0.2M Tris pH 7.5 at 
45C for 15 minutes. After checking that the membrane was 
no longer radioactive it was then deemed ready for re­
probing.
Probe labelling: the Amersham Multiprime DNA labelling 
system was used with lOOng of probe per membrane. It was 
made up to 12 ul in water and denatured by heating at 97 
degrees C for 2 minutes. Thereafter 10 ul buffer, 5 ul 
primer/dNTP mix, 3 ul [alpha-32P]dCTP (30uCi), and 2 ul 
(2 units) DNA Polymerase I (Klenow fragment) were incu­
bated at 37 degrees C for at least 30 minutes.
The labelled probe then required to be separated from 
the unreacted labelled dCTP. This was done by running the 
reaction mixture through a Sephadex G50 column. The 
Sephadex was autoclaved in two volumes of TE buffer prior 
to use and then kept in the fridge.The column was pre­
pared by taking a long form glass Pasteur pipette, and 
scoring it with a diamond pen about 1" from the end. The 
cotton wool plug was then removed and a wad of silico-
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nised glass pushed towards the bottom using another 
pipette. The Pasteur pipette was then clamped in a verti­
cal position on a retort stand. Sephadex was then added 
to the column and washed down with TE until the settled 
Sephadex fills the column upto the dimple in the pipette. 
The column was prevented from drying out by washing with 
T E. Probe mixture was added to the top of the column and 
topped up with TE. Using a minimonitor,as soon as activi­
ty was detected moving down the column fractions of 2 
drops were collected into Eppendorf tubes. Twenty frac­
tions were collected and universal solution replaced in 
the column. Each tube was checked for activity by holding 
them against the probe of the monitor. On each occasion 
there should have been two peaks of activity, the first 
representing the labelled probe. The two or three frac­
tions of maximum activity were pooled and the volume 
roughly estimated by using a pipettor set at 20ul; they 
were kept aside in a lead pot. A 1ml aliquot was taken 
for estimation of the activity of the probe on a Beta 
counter. The HPV probes were full length genomic probes 
type 6/11, 16 and 18 obtained from Dr H Zur Hausen
(Deutches Krebsforschungzentrum, Heidelberg).
PCR
Target sequences on the LI open reading frame of HPV 
types 6, 11, 16 and 18 were amplified using general
primers GP5 and GP6. Each cycle consisted of denaturation 
at 94 degrees C for 20 seconds, annealing at 40 degrees C 
for 60 seconds and chain elongation at 72 degrees C for 
20 seconds. Full length genome of HPV types 6, 11, 16 and
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18 were used as positive controls. Negative controls were 
a fibroblast line (MRC5) and ddH20.
To avoid cross contamination, preparation of re­
agents, processing of patient material, the PCR and 
Southern blotting took place in different rooms. Positive 
displacement pipettes or single use Pasteur pipettes were 
used throughout. Subsequent confirmation and typing by 
Southern blotting was carried out by the method de­
scribed above.
EBV
EBV was also detected by Southern blot on the same 
samples. The EBV probe was a construct of the BAM H 1 
fragments of viral DNA for genes L, W, and d kindly 
provided by Dr PJ Farrell of the Ludwig Institute for 
Cancer Research, St. Mary's Hospital, London. Serology 
for EBV was performed using IgG antibody to viral capsid 
antigen. In those patients with a high titre (640 or 
greater) an early antigen titre was also performed to 
elucidate whether the patient was suffering an acute 
infection or a high variant of normal. The laboratory 
performing the titres use < 10 = no evidence of past 
infection, < 640 > or = 10 as evidence of past infection 
and > 640 as suspicious of acute infection. A four fold 
difference in titre was within the normal limits of the 
laboratory.
HSV
Endocervical swabs were placed into viral transport 
medium and transported to the laboratory on the same day
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for tissue culture. If overnight storage was required 
specimens were stored at 4 C. The swab was innoculated 
into cell lines of VERO and HEP 2 with Eagle1 s minimum 
essential medium (GIBCO) with Earle’s salts. This medium 
contained freshly added Nystatin and gentamycin and was 
incubated at 37 C overnight. It was then changed the 
following day to a maintenance medium with streptomycin 
and penicillin. The following day examination for cyto- 
pathic effect was performed. Tubes were read daily for 7 
days and if no virus was isolated they were discarded. If 
a positive cytopathic effect was noted then the solution 
was innoculated into fresh VERO and fibroblast cell 
lines. If a further cytopathic effect was noted HSV 
isolation was reported.
HIV
All patients had HIV testing by the ABBOTT RECOMBINANT 
HIV 1 / HIV 2 EIA prior to enrollment in the study. Those 
patients who were HIV seropositive had this test repeated 
upon enrollment into the study. The ABBOTT RECOMBINANT 
HIV 1 / HIV 2 EIA is a solid phase enzyme linked immu­
noassay utilising polystyrene beads coated with recombi­
nant proteins (Ej_ coli) representing HIV 1 core and 
envelope and HIV 2 envelope antigens.
All patients with a positive test had a confirmatory 
ENVACOR HIV 1 EIA performed prior to being given their 
diagnosis as to HIV seropositivity and upon enrollment 
into the study, this test, as well as the ABBOTT RECOMBI­
NANT HIV 1 / HIV 2 EIA was routinely repeated. The ENVA­
COR HIV 1 EIA detects antibodies directed against the HIV
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1 envelope and core proteins. The ENV bead detects anti­
bodies directed against gpl60 and gp41. The CORE bead 
detects antibodies directed against p24 and p55.
HIV 1 antigen was also tested for to aid in diagno­
sis and as a measure of immunosuppression. ABBOTT HIVAG-1 
test was used to detect HIV 1 antigen. Specimens which 
tested positive with the HIVAG-1 test were repeated and 
those with repeatedly reactive specimens were tested 
using the ABBOTT HIVAG-1 BLOCKING ANTIBODY. This uses a 
specific antibody neutralisation step followed by testing 
with ABBOTT HIVAG-1 to indicate the presence of HIV 1.
(viii) Bacteriological Investigations
Full microbiological investigation was performed for 
Syphilis, NG, CT, TV, CA, and GV. Specimens were taken as 
described above (jpage 67.). Those slides which had been 
Gram stained were examined by direct microscopy. The 
swabs taken from the urethra and endocervix were as 
plated onto Thayer's medium for NG culture and the plates 
incubated at 37 degrees C in C02 enriched atmosphere for 
48 hours. Tests for CT comprised an enzyme linked immuno­
sorbent assay (ELISA) and a direct immunofluorescent 
antibody technique (Microtrak, SYVA) on samples obtained 
from the endocervix as described above ( page 71). A high 
vaginal wet preparation in saline was read immediately 
for TV, and CA. Clue cells were taken as evidence of BV.
Serum was obtained and tested for Syphilis Treponemal 
Serology (VDRL, TPHA and if indicated an FTA).
(ix) Immunological investigations
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General
These comprise clinical staging as described in the 
introduction (pages 31-34) and categorised into the CDC 
classification for HIV disease. T4/ T8 subsets were per 
formed, as were p 24 antigen estimations: these are 
described above. Beta 2 microglobulin estimations were 
performed using the Pharmacia B2-micro RIA. Assays were 
performed on serum. The Pharmacia B2M RIA test used is a 
double antibody radioimmunoassay. B2M in the sample 
competes with a fixed amount of I 125 labelled B2M for 
the binding sites of the specific antibodies. Bound and 
free B2M are separated by the addition of a second anti­
body immunoadsorbent followed by centrifugation and 
decanting. The radioactivity in the pellet is then meas­
ured. The radioactivity is inversely proportional to the 
quantity of B2M in the sample.
Local cervical immunity
As stated in the declaration, this part of the study 
was performed in collaboration with Dr S Barton, of St 
Stephen's Hospital, London and Mr P Maddox of the Whit­
tington Hospital, London. This part of the study was 
commenced at a time when the main study was already well 
advanced, and therefore only 14 of the 50 HIV seroposi­
tive patients were enrolled. The remaining 13 patients 
HIV seropositive patients who partook in this part of the
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study were enrolled by Dr S Barton at St Stephen’s Hospi­
tal and these patients are not used in any other part of 
this thesis.
Colposcopically directed punch biopsies were ob­
tained from the cervices of 27 HIV seropositive women 
whose disease ranged from CDC stages 2 - 4 .  In the 
presence of colposcopically abnormal epithelium a biopsy 
was taken from the most abnormal area; if the cervix was 
colposcopically normal the biopsy was taken from the 
transformation zone. The biopsies were cut and stained 
using 2 monoclonal antibodies for Langerhans1 cell mark­
ers, S100 protein and T6 (CD1). Detailed description of 
this technique is described by Barton et al (92).
The concentration of Langerhans1 cells was measured 
both per unit area and per length of cervical epithelium 
and association sought with stage of HIV disease, CIN, 
HPV infection, smoking, p24 Ag, and T4 count.
(x) Statistical Methods
The study was originally designed in collaboration with 
Dr Jane Wadsworth of the Academic Department of Communi­
ty Medicine at St. Mary's Hospital and she has supervised 
the statistical analyses involved. In the original plan­
ning of the trial an incidence of lower genital tract 
neoplasia of 45% was assumed in the HIV seropositive 
patients and 10% in the HIV seronegative patients. With
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these incidences 40 subjects in the HIV seropositive 
study group would have been required, as would 40 sub­
jects in the HIV seronegative control group to give the 
study a power of 89%.
The questionnaire (appendix 4) was entered onto the St 
Mary's Medical School main frame computer to facilitate 
analysis. Statistical analyses have been performed using 
the McNemar test, the Chi Square with Yates correction, 
the Fisher Exact test with 95% confidence intervals or 
the Mann Whitney U test as appropriate. These tests were 
performed using the SSPS/PC statistical package (Version 
2). The test used is indicated alongside the results.
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Chapter 4 
Results
(i) Introduction
Presumed mode of HIV transmission is described, fol­
lowed by risk factors for CIN. The 7 unmatched HIV 
seropositive patients are then described.
All comparisons between HIV infected and noninfected 
patients use only the 43 case matched HIV seropositive 
patients. Where comparison of CIN, cervical viral detec­
tion, and immunosuppression was made, the entire group 
of 50 HIV seropositive patients was analysed.
Cytology, colposcopy and histology results are 
compared for the cervix, vagina and vulva. The results 
of virological testing for HPV by Southern blot and PCR, 
and the results for EBV as detected by Southern blot are 
then compared. Investigations performed to measure 
immunosuppression are then presented and associations 
demonstrated. Finally results of studies of Langerhans' 
cells are presented.
None of the patients enrolled in the study 
were either pregnant or on zidovudine therapy at the 
time of enrollment.
The tables, bar charts and scattergrams are shown 
on pages 96-122.
(ii) Transmission of HIV
In table 1 HIV infection "risk activity" is shown in 
the 43 HIV seropositive women and their case matched 
controls. All the control patients had had a negative
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HIV test performed in the last year, many of them were 
the ’’worried well” who had no high risk activities, 
however many had placed themselves at risk of HIV infec­
tion in the past. As was to be expected many more of the 
HIV seropositive patients had placed themselves at risk 
of HIV infection, thus becoming infected, than had the 
HIV seronegative controls. None of the control group 
patients admitted to having placed themselves at in­
creased risk of HIV infection since testing. None of 
the patients enrolled were haemophiliacs or the partners 
of haemophiliacs.
Thus from Table 1 the following ascribed mode of 
transmission for those patients who were HIV seroposi­
tive was derived: thirty one (62%) of the 50 patients 
were thought to have acquired their HIV infection by 
intravenous drug use and 19 (38%) by heterosexual con­
tact. Amongst the 43 matched HIV seropositive patients 
27 (63%) were thought to have acquired their infection 
by intravenous venous drug use and 16 (37%) by hetero­
sexual contact.
(iii) Matching for CIN risk factors
As described above, the variables used for matching the 
control group were age (bar chart 1), age at first 
sexual intercourse (bar chart 2), total number of sexual 
partners in lifetime (bar chart 3) and smoking; as these 
were individually matched the number of controls and 
cases in each band are by definition, the same. With 
respect to age no patients were less than 20 years, 20 
(46.5%) were between 20 and 29 years, 19 (44%) were 
between 30 and 39 years and 4 (9.5%) were 40 years or
83
over. Ten (23%) of the patients had first had sexual 
intercourse at less than 16 years and 33 (77%) at 16 
years or greater. Eight (19%) had had 1-10 partners, 21 
(49%) had had 11-40 partners and 14 (32%) had had > 40 
partners.
Twenty eight (65%) of both the study and control 
groups gave a current history of smoking. Thirty three 
(66%) of the 50 HIV seropositive patients gave a cur­
rent history of smoking. A current history of smoking 
included those who had given up within the previous 6 
months. A further 5 patients were previous smokers who 
had stopped 6 months or more before enrollment into the 
study and were therefore considered non smokers.
The bar charts also show the matching parameters for 
the entire HIV seropositive group (n=50). They demon­
strate that the matched 43 patients are not significant­
ly different from the entire group.
Analysis was performed to detect if there were any 
potentially significant differences between the study 
and control groups with respect to current oral contra­
ceptive pill use and past cervical cytological findings. 
Five (12%) of the 43 HIV seropositive patients and 9 
(21%) of the HIV seronegative patients were currently 
taking the oral contraceptive pill; this is not a sta­
tistically significant difference.
Table 2 shows the comparison between the study and 
control groups with respect to past cervical cytology. 
No statistically significant difference was demonstrat­
ed.
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Table 3 demonstrates the matching parameters in the 7 
unmatched patients.
(iv) Cytology, colposcopy and histology.
Comparison and analysis were performed for the 43 HIV 
seropositive and seronegative patients and the 7 non­
matched patients were not considered. Fifteen (35% (Cl: 
21%-51%)) of the 43 case matched HIV seropositive pa­
tients and 8 (19% (Cl: 8%-33%)) of the 43 HIV seronega­
tive controls had evidence of CIN on cytology, whereas 
6 (14% (Cl: 5%-28%)) and 4 (9% (Cl: 3%-22%)) respective­
ly had histologically confirmed CIN. In addition, 4 (9%) 
of the 43 HIV seropositive patients and 1 (2%) of the 
HIV seronegative patients had intra epithelial neoplasia 
elsewhere in the lower genital tract (VAIN & VIN). These 
differences were not statistically significant. 95% 
Confidence Intervals were also performed for the differ­
ence between the two groups with respect to CIN as 
detected on histology and this was -8% - 18%.
The results described above of cytology, colposcopic 
findings, and histology of the cervix, vagina and vulva 
for the HIV seropositive and negative patients are shown 
in the Tables 4-7. The p value for each analysis and the 
test used are shown at the foot of each table.
(v) Virological Investigations
Table 8 shows the number and percentage of patients in 
whom cervical infection with HPV and EBV was detected by 
Southern blot. Results of HPV detection by PCR are shown 
in Table 9. HSV as detected by tissue culture was
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present in the cervices of none of the patients in the 
study. It was found to be present in the vulvae of one 
HIV seropositive and one HIV seronegative patient. An 
association was sought between HPV and CIN, and EBV and 
CIN, but none was demonstrated.
EBV serology shown in Table 10 demonstrated evidence 
of past infection in all cases and controls. Two pa­
tients from each group had reciprocal IgG titres of 
1280, a result which in the absence of HIV infection is 
highly suggestive of primary infection.
Investigation was also performed for hepatitis B 
surface antibody serologically, for herpes simplex virus 
by tissue culture, and for molluscum contagiosum clini­
cally. Statistical analysis was performed for hepatitis 
B using the Fisher Exact test. The results are presented 
in Table 11.
(vi) Bacteriological investigations
The results of bacteriological investigations are pre­
sented in Table 12. Culture and microscopy results have 
been combined for N^ gonorrhoeae. Microtrak and ELISA 
testing for C^ trachomatis are also combined. None of 
the patients studied had lymphogranuloma venereum, 
chancroid or granuloma inguinale. Since numbers were 
small no statistical analysis was performed.
(vii) Immunological investigations:
Clinical
Of the 50 HIV seropositive patients 18 (36%) were CDC
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stage 2 and 27 (54%) were CDC stage 3. Five (10%) of the 
patients showed evidence of clinical immunosuppression 
(CDC stage 4) (see pie chart 1). Significant association 
between cytological and histological findings and CDC 
staging is shown in Tables 13 and 14. Cytological and 
histological evidence of koilocytosis in the presence of 
CIN was not additionally considered and koilocytosis in 
the absence of CIN was grouped with normal cytological 
and histological results for the purposes of analysis.
Table 15 shows the comparison of CDC stage of HIV 
disease and virology results on the 50 HIV seropositive 
patients analysed. Statistical analysis was made using 
the FE test and no associations were demonstrated.
Laboratory
Significant association between CIN and laboratory 
markers of advancing HIV disease was found and is shown 
in Scattergrams 1, 2 & 3 and tables 16 & 17 (T4 count - 
scattergram 1, beta 2 microglobulin - scattergram 2 & 3 
and p 24 antigenaemia - tables 16 & 17). No association 
was found between cervical viral detection and clinical 
(Table 15) or laboratory evidence of HIV related immuno­
suppression.
Scattergrams 4 & 5 show T4 count and beta 2 micro­
globulin plotted against CDC stage of HIV disease. As 
described in the introduction i(pages 33-34 and 37-38 
respectively) these tests are known to correlate with 
increasing immunosuppression and thus advancing HIV
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disease. Scattergrams 4 & 5 demonstrate that as expected 
T4 counts fell and beta 2 microglobulin levels rose with 
advancing HIV disease.
(viii) Local immunology in the cervix (n=27)
The cervical epithelium of immunocompromised women with 
HIV infection contains significantly fewer Langerhans1 
cells per unit area as measured by S100 compared to non 
immunocompromised HIV seropositive patients. This is 
demonstrated in Table 18, p = 0.04.
Analysis of these T6 and S100 markers with respect to 
area and length of biopsy was performed to seek an 
association with CIN, HPV infection, smoking, T4 count 
and p24 Ag. This showed no association between any of 
these parameters. Thus, it can be concluded that the 
reduction in Langerhans1 cells per unit area in immuno­
compromised patients would appear to be independent of 
the other parameters studied.
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Table 1
"Risk" factors for HIV infection
HIV seropositive HIV seronegative 
(n=43) (n=43)
HIV partner 19(44%) 1(2%)
Homo.partner 9(21%) 13(30%)
Blood trans. 4(9%) 4(9%)
'’African” 14(33%) 15(35%)
"USA" 8(19%) 20(47%)
IVDU part. 22(51%) 8(19%)
Cur.IVDU 7(16%) 0
Past IVDU 24(56%) 6(14%)
HIV partner=sexual contact with known HIV infected 
partner, Homo. partner=homosexual or bisexual partner, 
Blood trans.=patient was the recipient of a blood trans­
fusion, "African"=African in origin and or lived for 1 
year in Africa, "USA" =partner from the USA, IVDU 
part.=IVDU partner, Cur. IVDU=current IVDU, Past IVDU=>6 
months since last IVDU.
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Table 2
Past Cervical Cytology
Normal! 
Koilo.
CIN
Not done 
Not avail.
HIV seropositive 
(n=43) 
24(55%)
0
8(19%)
5(12%)
6(14%)
HIV seronegative 
(n=43) 
30(70%) 
1(2%)
9(21%)
3(7%)
0
(Chi Square with Yates correction = 0.00096; p>0.05)
(Koilo. = koilocytosis, N. avail. = not available; ie. 
cytology performed in other centre and patient did not 
know the result)
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Table 3
Matching parameters in the 1_ unmatched patients.
Age Coitarche Smoking No. of p«
Patient 1 22 15 yes >40
Patient 2 25 15 yes >40
Patient 3 40 20 no 5
Patient 4 28 16 yes >40
Patient 5 72 17 no >40
Patient 6 27 16 yes >40
Patient 7 28 17 yes >40
(coitarche=age of first sexual intercourse)
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Table 4 
Cytology
HIV seropositive HIV seronegative
(n=43) (n=43)
Normal} 25(58%) 33(77%)
Koilo.} 3(7%) 2(5%)
CIN 1) 9(21%) 7(16%)
CIN 21 4(9%) 0
CIN 3) 2(5%) 1(2%)
Inv. 0 0
Unsuit. 0 0
Normal/koilo. was compared with CIN: no significant 
difference was found, p>0.05, X2 with Yates correction 
=2.14.
(koilo. = koilocytotic atypia, in the presence of no 
other abnormality, CIN = changes suggestive of cervical 
intraepithelial neoplasia, Inv. = cytological changes 
suggestive of invasive carcinoma, unsuit. = unsuitable)
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Table 5
Colposcopy of the cervix
Normal 24(56%)
HIV seropositive 
(n=43)
HIV seronegative 
(n=43) 
31(71%)
A-W 18(42%) 8(19%)
Warts 1(2%) 2(5%)
Malig. 0 0
Inad. 0 2(5%)
Analysis was not performed due to the subjectivity of 
colposcopy.
(A-W = aceto white areas seen, Malig. = appearance 
suggestive of invasive malignancy, Inad. = inadequate ie 
squamo-columnar junction not visualised)
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Table 6
Histology of the cervix
HIV seropositive HIV seronegative
(n=43) (n=43)
3(7% 3(7%)
24(55%) 31(72%)
10(23%) 5(12%)
2(5%) 2(5%)
2(5%) 1(2%)
2(5%) 1(2%)
0 0
Normal, not done and koilocytosis were compared with CIN 
and no significant difference was found, p>0.05, X2 with 
Yates correction = 0.113.
( koilo. = koilocytotic atypia, CIN = cervical 
intraepithelial neoplasia, Inv. = invasion, Not done = 
since colposcopy was normal)
Normal
Not done
Koilo.
CIN 1
CIN 2
CIN 3
Inv.
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Colposcopy of the vagina, vulva and perianal area
HIV seropositive HIV seronegative
(n=43) (n=43)
VAIN 1(2%) 1(2%)
VIN 3(7%) 0
PAIN 0 0
Wart vag. 2(5%) 1(2%)
Wart vul. 5(12%) 6(14%)
Wart p.an. 3(7%) 2(5%)
Numbers were too small to allow any meaningful statisti­
cal analysis.
VAIN, VIN and PAIN were diagnosed histologically.
(VAIN = vaginal intraepithelial neoplasia, VIN = vulval 
intraepithelial neoplasia, PAIN = perianal intraepithe­
lial neoplasia, Wart vag. = appearance suggestive of 
vaginal HPV infection, Wart vul. = appearance suggestive 
of vulval HPV infection, Wart p.an.= appearance sugges­
tive of perianal HPV infection.)
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Table 8
HPV and EBV detection by Southern blot. 
Southern blot
HIV seropositive HIV seronegative
(n=43) (n=43)
No. (*) No. (%) p value
2
X
HPV 6/11 5 (12%) 1 (2%) <0.25 1.5
HPV 16 5 (12%) 2 (5%) <0.5 0.57
HPV 18 3 (7%) 6 (14%) <0.75 0.44
Total HPV 12 (28%) 9 (21%) <0.75 0.24
EBV 9 (21%) 5 (12%) <0.5 0.64
(McNemar test)
One HIV seropositive patient was not tested for HPV, 
two patients had both HPV 6/11 and 16/18. Three of the 
HIV seropositive patients who had HPV also had EBV.
Table 9
HPV detection by PCH
PCR
HIV seropositive HIV seronegative
No. (%) No. (%) p value X*
(n=43) (n=43)
HPV 6/11 3 (7%) 1 (2%) <0.75 0.25
HPV16 5 (12%) 5 (12%) - 0
HPV18 2 (5%) 8 (19%) <0.10 3.12
Unid. HPV 5 (12%) 3 (7%) <0.75 0.25
Total HPV 15 (35%) 17 (40%) <0.9 0.06
(No. = number of patients, % = percentage of patients, 
unid. = unidentified)
(McNemar test)
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Table 10
Results of EBV serology
HIV seropositive HIV seronegative 
Titre (n=36) (n=37)
0-9 0 0
10-640 34 35
>640 2 2
A titre of 0-9 is interpreted as indicating no past 
infection, 10-640 as evidence of past infection and >640 
as possible recent infection.
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Table 11
Virological Investigations
HIV seropositive HIV seronegative
(n=43) (n=43)
HB 12(28%) 0
HSV 1(2%) 1(2%)
MC 2(5%) 1(2%)
Warts 4(9%) 7(16%)
(HB = hepatitis B surface antibody, HSV =
p=0.0001
virus, MC = molluscum contagiosum, Warts = macroscopic 
warts and do not include those identified with the 
colposcope)
(Fisher Exact test)
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Table 12
Bacteriological investigations.
HIV seropositive
(n=43)
GC 0
TV 3(7%)
CT 0
CA 7(16%)
BV 3(7%)
STS 1(2%)
(GC = N. gonorrhoea, TV = 
Chlamydia trachomatis, 
serology, CA = Candida 
vaginosis. )
HIV seronegative 
(n=43)
1(2%)
0
0
8(19%)
5(12%)
0
Trichomonas vaginalis, CT = 
STS = syphilis treponemal 
albicans, BV = bacterial
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Table 13
CDC stage of HIV disease and cervical cytology (n=50)
Non immunocompromised Immunocompromised
CDC 2&3 CDC4
(n=45) (n=5)
Normal} 31 0
Koilo.i 3 0
CIN 11 5
Comparison was made between normal/koilo. and CIN by 
the Fisher Exact test, p = 0.0014 
Difference = 78% (95% Cl: 66% - 90%)
(CIN may or may not include koilocytosis, Koilo. = 
koilocytosis alone with no evidence of CIN)
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Table 14
CDC stage of HIV disease and cervical histology
Non immunocompromised Immunocompromised 
CDC 2&3 CDC 4
(n=45) (n=5)
Normal! 32 0
Koilo. } 11 1
CIN 2 4
Comparison was made between normal/koilo. and CIN by the 
Fisher Exact test, p = 0.0003 
Difference = 76% (95% Cl: 40% - 100%)
(CIN does not include koilocytosis, Koilo. = koilocyto­
sis alone with no evidence of CIN)
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Table 15
CDC stage of HIV disease and virology results
Non immunocompromised Immunocompromised
CDC 2&3 CDC4
(n=45) (n=5) p value
HPV 6/11 5 0 0.57
HPV16/18 9 2 0.94
Total HPV 12 2 0.87
EBV 9 0 0.35
Two patients had HPV 6/11 and 16/18 concurrently. One of 
the immunocompromised patients did not have analysis 
performed for HPV.
(Fisher Exact test)
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Table 16
P 24 antigen and cervical cytology
p 24 antigen positive p 24 antigen negative 
(n=7) (n=36)
Normal} 4 21
Koilo.j 0 3
CIN 3 (43%) 12 (33%)
Fisher Exact test , p = 0.47 
Difference = 9.5% (Cl: -30% - 40%)
(CIN and normal/koilocytosis were compared)
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Table 17
P 24 antigen and cervical histology
p 24 antigen positive p 24 antigen negative 
(n=7) (n=36)
Normal^ 4 22
Koilo.) 0 11
CIN 3 (42.9) 3 (8.3%)
Fisher Exact test, p = 0.0447 
Difference = 34% (Cl: -3% - 72%)
(CIN and normal/koilocytosis were compared)
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Table 18
Comparison of SlOO/unit area with Stage of HIV disease
Disease Stage No median rank z value
Asymptomatic 5 18 14.9 0.28
PGL 15 7 14.3 0.22
ARC 1 8 14.0 0.00
AIDS 6 4 12.5 -0.52
Total 27
No. = number of patients, median = median
SlOO/unit area •
Wilcoxon Rank Sum test p = 0 .04
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Chapter 5 
Discussion
(i) Mode of HIV transmission and controlled parameters 
The HIV seropositive patients fell largely into 2 cate­
gories, namely indigenous patients who acquired the 
infection by intravenous drug usage and African patients 
with sexually acquired infection. However, it can often 
prove difficult to assign a single mode of transmission 
to HIV infected women, particularly IVDUs who also have 
HIV infected sexual partners.
The study group was enrolled in London and Glasgow, 
whereas the control group were enrolled exclusively in 
London. However, the racial characteristics of patients 
in the control group were similar to that of the study 
group. Oral contraceptive pill use and past cervical 
cytology were not controlled for, however both the study 
and the control group were similar in these respects. An 
immunosuppressive effect of intravenous drug use in the 
absence of HIV infection has not been described. Howev­
er, in those patients infected with HIV, intravenous 
drug use has been shown to increase HIV disease progres­
sion (75). It was therefore felt invalid to control for 
intravenous drug use.
In 7 of the HIV seropositive patients, a history of 
smoking, large numbers of sexual partners and early age 
of first intercourse precluded the enrolment of matched 
controls.
The HIV seronegative control group patients were 
selected from those women attending the genitourinary 
clinic with negative HIV tests and were matched for age,
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cigarette smoking, total number of sexual partners, and 
age of first sexual intercourse. The match made for 
smoking was based on a history of current smoking; to be 
classified as "non smoking" the patient had to have 
stopped smoking for more than 6 months. This period was 
selected arbitrarily. Ex-smokers tend to have Langer- 
hans' cell counts between those of smokers and non- 
smokers (92). It was not possible to match for a history 
of being an "ex-smoker" or to make allowance for specif­
ic numbers of cigarettes smoked.
None of the HIV seropositive patients in the study 
were either pregnant or taking zidovudine at the time of 
enrolment, and these factors are therefore not confound­
ing variables.
(ii) Cytology and histology
Those patients with normal colposcopic findings, but 
cytology suggestive of CIN 2 or 3 on 2 consecutive 
occasions, had a diagnostic and therapeutic cone biopsy 
performed. The discrepancy between cytological and 
histological findings occurred because patients with 
cervical cytology suggestive of CIN 1 in the presence of 
normal colposcopic findings did not necessarily undergo 
cervical cone biopsy. These patients were either re­
viewed colposcopically at 6 monthly intervals or if they 
preferred, a cone biopsy was performed after 2 consecu­
tive smears showing mild dyskaryosis. For this reason, 
in several cases where smears showed mild dyskaryosis, 
histological confirmation of CIN was not available.
A lower prevalence of CIN in HIV seropositive women
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(14%) has been shown than that found in previously 
published studies (3-7, 11, 12). The earlier sudies may 
have been biased towards patients with symptomatic HIV 
disease. It is also possible that there were a lower 
number of IVDUs amongst the HIV seropositive group in 
this study than those previously reported (3-7, 11, 12), 
this was certainly the case with the work of Shafer et 
al (12). In this study we actively sought out and re­
called HIV positive women for colposcopic assessment, 
rather than recruiting patients routinely attending the 
genitourinary medicine clinic. We may therefore have 
selected a group of patients who are currently less 
sexually active and arguably less symptomatic with 
regard to their HIV disease (90% CDC stages 2&3).
(iii) Bacteriological findings
The incidence of STDs is surprisingly low (0% GC,
0% CT) in those infected with HIV and (2% GC, 0% CT) in 
the control group, particularly for a group of women 
many of whom had had multiple sexual partners. This, 
however may reflect their close medical supervision in 
the department of genitourinary medicine. Candida albi­
cans is a common opportunistic infection in symptomatic 
HIV infected women. The majority (45/50) of the women in 
this study were, however not clinically immunocompro­
mised and therefore, as would be expected there is no 
difference between the HIV seropositive and seronega­
tive groups.
(iv) Virological findings
Twelve (33%) of the HIV seropositive patients and 9
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(21%) of the HIV seronegative controls had cervical 
infection with HPV 6/11, 16, and 18 detectable by South­
ern blot. There was no statistically significant differ­
ence between the HIV seropositive and seronegative 
groups with regard to the detection of HPV types on 
testing by Southern blotting. PCR showed a higher preva­
lence of HPV 18 in the HIV seronegative women, this did 
not however reach statistical significance. By control­
ling closely for CIN risk factors, it was not expected 
that there would be a difference in the prevalence rates 
of HPV infection as detected by PCR. Higher detection 
rates for HPV and EBV by Southern blotting might have 
been expected in the HIV seropositive group since HIV 
related immunosuppression could be expected to enhance 
viral replication once infection has occurred. This was 
not seen, perhaps because of the low number of signifi­
cantly immunosuppressed patients in this study.
In the past koilocytosis, as detected by cytological 
and histological analysis, was presumed to be evidence 
of HPV infection, however its lack of sensitivity and 
specificity are well known (171). In this study the much 
more specific and sensitive techniques of Southern 
blotting and PCR have been used. Analysis of the data on 
koilocytosis has not been performed.
Nine (21%) of the HIV seropositive and 5 (12%) of the 
HIV seronegative patients had EBV detected in the cervix 
by Southern blot and all the cases and controls had 
serological evidence of past infection. HIV infection is 
associated with a polyclonal gammopathy (160) and this 
may explain the high reciprocal EBV IgG titre of 1280
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obtained in 2 of the HIV seropositive patients. However, 
a similar titre in 2 of the HIV seronegative patients 
may represent acute EBV infection, a phenomenon previ­
ously associated with viral shedding from the cervix 
(161).
No statistical association was found between cervical 
infection with HPV or EBV and CIN in either the HIV 
seropositive or negative groups. The number of patients 
enrolled in this study was however small and these 
results have no statistical power to refute an associa­
tion of these viruses to CIN.
Testing for other viral infections revealed a small 
number of patients to have molluscum contagiosum, warts 
and herpes simplex virus. No difference was found be­
tween the HIV seropositive and negative patients. Test­
ing however for hepatitis B surface antibody, a marker 
of past infection with hepatitis B, showed a highly 
significant difference between the two groups of pa­
tients (12 (28%) in the HIV seropositive patients 
versus 0 in the controls). This was to be expected since 
the mode of transmission of HIV and hepatitis B are 
similar and hepatitis B is known to be the much more 
infectious agent (168); The lack of hepatitis B in the 
control group reflects not having recruited HIV seroneg­
ative IVDUs.
(v) Immunosuppression
An association was sought between abnormalities de­
tected on cervical cytology and histology and the stage 
of HIV disease (CDC stages 2 and 3 were considered
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together). Cytology and histology results were classi­
fied into 3 categories: normal, koilocytosis and CIN 
(CIN 1, 2 and 3 combined). For analytical purposes 
cytologically and histologically diagnosed koilocytosis 
in the absence of CIN was grouped with normal. This was 
felt to be valid since, although koilocytosis is not 
normal per se it is not a precursor of CIN.
A significant association was found between clinical 
immunosuppression and CIN as detected both cytologi­
cally (p = 0 .0014, CI = 66-90% ) and histologically 
(p=0.0003, CI=40-100%). This finding is in accordance 
with those of previous studies which have shown an 
increased incidence of CIN and invasive cancer in iatro- 
genically immunosuppressed patients (13-24) and in those 
patients with advanced HIV disease (12).
The laboratory markers of HIV related immunosuppres­
sion used in this study are known to correlate with each 
other and with worsening HIV disease (61-64, 68-70); the 
results in this study concurred with these findings. 
Although this study was not designed to investigate 
this, confirmation is useful since previous studies have 
been hampered by innacurate laboratory results. Scatter- 
grams 4 & 5 show the expected trends in T4 count and 
beta 2 microglobulin with advancing HIV disease. The 
lack of association of p 24 antigenaemia with advancing 
HIV disease is most likely due not to laboratory error, 
but to the small numbers of patients involved.
In this study reducing T4 cell numbers (p=0.0037), 
rising beta 2 microglobulin levels (p=0.037) and the 
presence of p 24 Ag (p=0.0447) were independently asso­
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ciated with an increasing incidence of CIN as detected 
histologically, and for beta 2 microglobulin this was 
also the case cytologically (p=0.0184). There was no 
association between immunosuppression as measured in 
this study and the detection of EBV or HPV in the cer­
vix.
The lack of association demonstrated may be due to 
there being small numbers of significantly immunocompro­
mised patients in this study.
(vi) Langerhans' cells
Progressive HIV disease as measured clinically resulted 
in a reduction in the marker S100 of Langerhans1 cells 
per unit area of cervical epithelium. No other associa­
tions were shown. This suggests that this association 
is independent of the known effect of smoking and HPV 
infection on Langerhans1 cells. Failure to show an 
association with CIN, HPV, smoking, and falling T4 count 
is probably a reflection of the small number of patients 
enrolled in this part of the study.
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Chapter 6
Conclusions 
(i ) General
In conclusion, it has been shown that 14% of the HIV 
infected women had CIN detectable by histological analy­
sis and that immunosuppression predisposed towards 
cervical intraepithelial neoplasia as detected both 
cytologically and histologically. There was an increased 
detection of HPV 6, 11, 16, and EBV from the cervix in 
HIV infected women; this difference did not reach sta­
tistical significance. In this study HIV infection per 
se did not appear to significantly increase the risk of 
CIN developing, but immunosuppression as a result of HIV 
infection did increase this risk. Cervical Langerhans1 
cells have been shown to be reduced with advancing HIV 
disease and although it has not been demonstrated in 
this study, it may contribute to the association of 
neoplasia with advancing immunosuppression.
Prospective follow up of these patients is currently 
in progress and an increasing incidence of CIN and 
possibly increasing cervical detection of HPV and EBV 
may be expected, as these patients become progressively 
more immunocompromised.
Originally four hypotheses were to be tested:
(i) That HIV infection predisposed to cervical neopla­
sia.
(ii) That the cervical neoplasia would be as a direct 
result of HIV related immunosuppression
123
and/or
(iii) That this cervical neoplasia might be as a result 
of immunosuppression causing increased expression of 
HPV and EBV in previously infected cervical epithelium, 
and/or
(iv) as a result of decreased immune surveillance in the 
cervix.
This study suggests that hypothesis (i) is only true 
when patients are immunocompromised which confirms 
hypothesis (ii). These data do not, however, have the 
power to refute hypothesis (i), however the 95% Cl of 
the difference between the respective incidences of CIN 
of -8% - 18% suggests thatj if there is a difference 
between the two groups it is less than 20% and therefore 
much less than the difference originally postulated (45% 
versus 10%). Although it has failed to answer hypothesis
(iii), a study of this size was unlikely to succeed in 
this respect. It is not possible to draw from this study 
the opposite conclusion "that these viruses do not 
predispose to CIN" since the data carries no statistical 
power in this respect. With respect to hypothesis (iv) 
a reduction in Langerhans1 cells has been shown, but 
this has not been shown to associated with cervical 
neoplasia in this study.
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(i i) Management
In the light of these results annual cervical cytology 
and colposcopy for HIV seropositive women who are not 
immunosuppressed either clinically or by laboratory 
investigation is advised; this is in contradistinction 
to previous guidelines (3). In those patients who are 
immunocompromised, more frequent assessment may be 
desirable.
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Appendices
(i) HIV transmission
HIV has been shown to be transmitted by three routes: 
sexual, blood-to-blood, and materno-foetal contact. This 
has been derived from epidemiological studies and well 
documented anecdote. The mode of HIV transmission of the 
St Mary's cohort is demonstrated in the enclosed publi­
cation (172). HIV is an organism which survives very 
poorly outside the body, making very close contact 
necessary for person to person transmission. Its poor 
survival is due to its very fragile outer lipid mem­
brane derived during budding from the infected host 
cell. Various properties of HIV make it less infectious 
than Hepatitis B infection (See appendix 2, (170)).
Sexual transmission of HIV can occur amongst hetero­
sexuals through vaginal intercourse or anal intercourse 
and in homosexuals by anal intercourse. Although a 
single exposure to an infected individual is all that is 
required for transmission, risk rises with a rising 
number of sexual partners. This has been reflected 
geographically whereby homosexual transmission is most 
common in the USA, Europe and Australasia whilst hetero­
sexual transmission is most common in Africa, the Carib­
bean, and South-East Asia. Where spread occurs by other 
means eg. intravenous drug abuse, this can form a bridge 
for further sexual spread, particularly since many IVDUs 
fund their drug habit by prostitution. Previously there 
was much emphasis placed on specific aspects of sexual 
contact in the transmission of HIV, this does not tend
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to be borne out by the evidence. Mucosal trauma, geni­
tal ulceration, practices such as "fisting" amongst 
homosexuals and anal intercourse were thought to repre­
sent special risk since trauma occurs more readily. It 
would appear, that rather than the act being causal, it 
reflects that these practices are most prevalent in the 
most sexually active persons. The virus is present in 
blood and genital secretions and trauma and genital 
ulceration therefore, although facilitating spread, are 
not essential for transmission.
Early on in the HIV epidemic attention focussed on 
spread through blood products particularly amongst 
haemophiliacs receiving factor concentrate, and the 
potential for spread to health care workers by needle 
stick injury. Screening of donors by the blood transfu­
sion service has virtually eliminated the risk from 
blood products. The risk to health care workers appears 
to be slight (see appendix 2 (170)).
The use of intravenous injections by drug users 
sharing needles and syringes is the most frequent means 
of blood to blood transmission, particularly if the 
syringes are flushed with blood to prevent drug wastage. 
Local sharing practices and relative immobility on the 
part of IVDUs have produced marked regional variation. 
Currently, areas such as New York, New Jersey and in 
Scotland, Edinburgh and Dundee have high incidences of 
HIV infection in contrast to Glasgow, which whilst having 
many IVDUs, has a relatively low incidence of infection.
Materno-foetal transmission occurs mostly transplacen- 
tally, although transmission may occur at birth or rarely
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by breast feeding. Infectivity may be related to the 
stage of maternal HIV disease and is approximately 13% 
(173).
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(ii) HIV and health care workers
The risks of HIV and hepatitis B infection for health 
care workers are discussed in the enclosed editorial 
(170).
(iii) Psychiatric manifestations
The psychiatric manifestations of 25 of this cohort of 
HIV positive women and a number of the HIV seronegative 
controls have been studied. A reprint of these results 
is enclosed (174).
(iv) Questionnaire
The questionnaire used for all patients enrolled in 
the study is found on the following pages.
(v) HIV and fertility/infertility
These issues are addressed in the two enclosed publica­
tions (175, 176).
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Reducing the risk of infection for obstetricians
The exposure of surgeons to needlestick injury 
and contamination with blood places them at 
risk of infection with hepatitis B virus (HBV) 
and more recently with human immunodefi­
ciency virus (HIV). HBV has the lower mor­
tality rate but is highly infectious and HIV, 
although much less infectious, carries a fatal 
prognosis. HBV would appear to be the most 
important occupational infection in health care 
workers in the developed world whilst HIV 
probably stimulates the most anxiety.
In addition to the greater infectivity of HBV, 
it is a much more resilient virus than HIV, sur­
viving air drying and disinfection to a greater 
degree; this may facilitate transmission by 
environmental contamination of fomites.
Following needlestick injury from a patient 
with HBV, the seroconversion rate is 25% if the 
patient is HBe antigen positive and 5% if he is 
HB surface antigen positive in the absence of e 
antigen (Hadler 1990). Where the patient is HIV 
seropositive, needlestick injury carries a sero­
conversion rate of approximately 0-2% (Ippolito 
et al. 1990). Needlestick injury involving the 
injection of an inoculum understandably carries 
the greatest risk.
Rates of needlestick injury amongst surgeons 
are difficult to ascertain due to a low level of 
reporting, whereas glove puncture is readily 
measureable. Glove puncture represents poten­
tial needlestick injury and facilitates contam­
ination of the surgeon’s skin with infected 
material. The degree of contamination will 
depend on the size and length of time the perfor­
ation is present. Smith & Grant (1990) have 
shown that glove puncture in obstetricians 
occurs in 54% of caesarean sections and, where 
such perforations were recognized by the sur­
geon, 60% of them occurred during closure of 
the lower segment of the uterus. The frequency 
of glove puncture has been shown to increase 
with increasing length of the surgical procedure 
but, surprisingly, there is a lack of correlation 
with emergency surgery.
The seroconversion rate for HBV and HIV 
amongst health care workers is unknown fol­
lowing skin or mucous membrane contamina­
tion but is thought to be much lower than that
following needlestick injury. There are only 
three recorded cases of HIV seroconversion fol­
lowing such exposure and each of these had 
unusual features, including delayed seroconver­
sion and disseminated exposure in association 
with significant skin pathology.
In the USA it is currently estimated that 15 
health care workers die annually from fulminant 
hepatitis, 1000 become HBV carriers and a 
further 200-300 will eventually die due to the 
chronic consequences of HBV infection, namely 
cirrhosis and primary hepatocellular carcinoma 
(Hadler 1990). Despite this, the current uptake 
of HBV vaccine amongst health service person­
nel in the UK is still inadequate (87% uptake in 
orthopaedic surgeons (Williams & Flowerdew 
1990)). When HBV vaccine became generally 
available in 1982, uptake was initially poor, 
related perhaps to anxiety over its derivation. 
However, since 1987 genetically engineered vac­
cine has been available that is free from any 
potential pathogens and no adverse effects have 
been proven. More than 90% of infections with 
HBV in health care workers can be prevented by 
vaccination. In approximately 10%, an 
adequate course of vaccination will fail to mount 
a protective immune response, and presumably 
these individuals will remain at risk from infec­
tion (Westmoreland 1990). In view of its avail­
ability, reasonable cost, safety and effectiveness, 
we feel that HBV vaccination should be actively 
encouraged in all health care workers. Currently 
the medical profession are notoriously poor 
attenders at occupational health departments, 
but we believe this should become a requirement 
of their employment.
The standard HBV vaccination regimen com­
prises three injections with a 1-month interval 
between the first and second injection and a third 
injection 6 months after the first. This regimen 
results in peak antibody levels 1 month after the 
third dose, and therefore cannot provide rapid 
protection to individuals at high risk. It has been 
suggested that an accelerated vaccination sched­
ule (0, 4 weeks and 8 weeks) with a booster vac­
cination at one year, if required, may result in 
more rapid protection. Antibody levels should 
be measured at approximately 3 months after
the initial visit and if the result shows a non- 
protective response, a booster vaccination 
should be given. Thereafter antibody levels 
should probably be measured every 3-5 years 
and if they fall below a protective level, a further 
booster is required. If these measures fail to 
stimulate an adequate antibody response the 
person should be informed that he is not fully 
protected against HBV and should be advised to 
undergo post exposure prophylaxis with hyper­
immune gammaglobulin as the need arises.
Reduction of risk for surgeons requires a one 
tier approach to infection control. Such a policy 
must include the wearing of gloves, waterproof 
gowns and goggles or protective spectacles 
during any procedure that may involve possible 
contamination with patients’ body fluids. Addi­
tionally, any patient known to be seropositive 
should be placed last on the theatre list to facili­
tate thorough disinfection of the operating the­
atre following the procedure. A two tier 
infection control policy is likely to induce appro­
priate caution in the surgeon when he is aware of 
the patient’s seropositivity, but also encourages 
a less careful approach in the management of 
those patients who are perceived to be at low risk 
of infection. Most patients have not been tested 
for either virus and of course many do not dis­
close ‘at risk’ behaviour. Furthermore, patients 
who have been recently infected may have nega­
tive antibody tests thus giving falsely reassuring 
results.
For an infection control policy to be effective, 
it must be universally implemented. A  recent 
study conducted in an accident and emergency 
department demonstrated poor compliance with 
such a policy. Health personnel cited as reasons 
for lack of compliance, the perceived loss of 
manual dexterity and lack of time to implement 
the appropriate techniques. These excuses sug­
gest complacency in the face of serious potential 
infection.
Double gloving reduces by a factor of six the 
frequency of inner glove puncture, with little 
loss in operator sensitivity (Matta et al. 1989). 
Glove manufacturers are currently developing 
gloves strengthened in the digits since this is the 
area most prone to puncture. Blunt tipped 
needles appear to reduce the frequency of glove 
puncture whilst being capable of perforating 
uterine muscle (J. M. Grant, personal communi­
cation) and cervical tissue (C. Hauxwell, per­
sonal communication). Special forceps for 
suturing the uterine wound during caesarean
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section are being developed and may reduce the 
risk of glove puncture. The use of staples during 
closure of the skin and internal wounds will 
further reduce the amount of suturing required, 
thus diminishing the puncture rate.
Nonoxynol-9 has been shown to have anti 
HIV properties in vitro. This has caused some 
surgeons, particularly in the USA, to smear non­
oxynol-9 on their hands before donning surgical 
gloves. This is a practice with far from proven 
benefit. Nonoxynol-9 may increase skin per­
meability and thus, theoretically, increase the 
potential for infection with either HIV or HBV 
(Jeffries 1990).
Following exposure to potential infection by a 
needlestick injury a number of steps should be 
taken: the person should immediately decon­
taminate the wound by encouraging free flow of 
blood and by washing the area thoroughly with 
disinfectant. Expert counselling should be avail­
able to discuss the risk of infection by HBV and 
HIV. Serum should be saved for possible future 
HIV testing. In the event of subsequent serocon­
version this allows prior seronegativity to be 
confirmed.
In those not previously vaccinated for HBV, a 
course should be instituted as soon as possible 
and hyperimmune globulin administered within 
72 h. The fast induction regimen for HBV vac­
cination is also appropriate for post-exposure 
prophylaxis. In view of the fact that HBV infec­
tion usually has an incubation period of 2 or 
more months, post-exposure vaccination alone 
may be sufficient in most cases.
Where a needlestick injury involves a known 
HIV seropositive patient, post exposure prophy­
laxis with zidovudine can be given, although this 
is of unproven benefit. To maximize the poten­
tial benefit, zidovudine should be given as soon 
as possible, preferably within 1 hour and not 
later than 24 hours after injury. It is currently 
prescribed at high dosage (1200 mg/day) for 6 
weeks and as yet no serious side effects have 
been reported (Gerberding 1990). No data are 
available on the long term toxicity of this regi­
men. Due to the low HIV seroconversion rate 
following needlestick injury and the lack of 
enthusiasm shown by health care workers for 
placebo treatment, it is unlikely that the efficacy 
of zidovudine in post-exposure prophylaxis will 
ever be proved.
Reducing the risk of HBV infection in sur­
geons requires a substantially increased uptake 
of HBV vaccination. Current surgical practice
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also requires modification to reduce the risk of 
inoculation injury and skin and mucous mem­
brane contamination. A  high grade one tier 
infection control policy, coupled with the use of 
a combination of the measures described above, 
would greatly reduce the risk to obstetricians 
and gynaecologists of HBV and HIV infection.
J. R. Smith 
Research Fellow, 
Gynaecology and Genitourinary Medicine
V. S. Kitchen
Senior Registrar, Genitourinary Medicine
The Jefferiss Wing 
St Mary's Hospital 
London W 21N Y
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Case summary
J R Smith, G E Forster, V S Kitchen, Y S Hooi, 
P E Munday, D B Paintin
A 31 year old woman and her 36 year old husband 
wished to be investigated and managed for infertility. 
In 1989 both had tested positive for antibodies to HI V-I. 
It was not possible from the clinical history to estimate 
when HIV seroconversion had occurred, but infection 
most probably occurred through heterosexual trans­
mission. The woman had conceived one pregnancy by 
a previous partner, and the husband had fathered three 
children by a previous partner. Before knowing their 
HIV antibody state they had had some investigations 
for secondary infertility and the woman had been 
treated with clomiphene. This was discontinued after 
her HIV state was known. The couple had been having 
unprotected sexual intercourse for two years without 
conception.
Before discussing infertility the couple was given 
prepregnancy counselling with respect to HIV to 
explain the pertinent facts about the natural history of 
HIV disease and the risk of vertical transmission. They 
were told that the vertical transmission rate in well 
HIV positive women is unknown but is probably 13- 
30%,12 at least in developed countries, and that it may 
be greater if the woman has symptoms of HIV 
infection,3 and that detecting HIV infection in utero is 
currently impossible and excluding HIV infection in 
the first 18 months of life is difficult. Furthermore, the 
risks to the infected mother are unknown, although 
theoretically the immunosuppressive effects of preg­
nancy may precipitate a deterioration in maternal 
condition.45
The couple were investigated after this initial 
counselling to determine the stage of HIV infection in 
each and to quantify their respective prognoses and 
that of their potential offspring. Clinical examination 
showed Centers for Disease Control stage IV-C2 
disease in the man and stage II disease in his wife.6 
Serum P24 antigen was not found in either patient and 
T4 lymphocyte numbers were low in the man and at 
the lower limit of normal in the woman. It is not 
possible to predict the long term prognosis for either 
prospective parent, but on average 39% of people will 
develop AIDS within 9*2 years of infection with HIV.7 
With time, it is likely that most people infected with 
HIV will develop AIDS. Survival thereafter depends 
on the particular manifestation of HIV related disease. 
This suggests that any potential offspring if not 
infected will be orphaned, at best as teenagers. This 
was explained to the couple.
After counselling, the couple seemed to be fully 
aware of the consequences of pregnancy for them and 
their potential offspring. Furthermore, they wished to 
have their infertility actively managed. They were
informed that although we were able to perform simple 
endocrinological and seminal investigations for in­
fertility, active management could not be promised as 
we were uncertain of the ethical implications. The 
couple felt that knowing the cause of their infertility 
would be helpful, and investigations were therefore 
performed. These suggested polycystic ovarian disease 
and oligospermia.
Legal analysis
Kathy Doyle, Linda Delany
DOCTORS LIABILITY TO PARENTS
Decisions concerning access to infertility treatment 
have received little legal attention. In the only relevant 
reported case the treatment at issue was in vitro 
fertilisation (IVF).8 The consultant refused to treat the 
(married) woman who sought it because of her history 
of prostitution and because Manchester City Social 
Services Department had rejected her applications to 
foster or adopt. The High Court judge assumed, but 
did not find as a matter of law, that the consultant’s 
decision was open to judicial review and should have 
been reached fairly; he also appeared to accept the 
relevance of criteria used by adoption agencies. Had 
the assumptions been formulated as legal principles, 
useful legal guidance for decisions on eligibility for 
infertility treatment would be available; as it is, the 
legal significance of the case is unclear.
When the Human Fertilisation and Embryology Act 
1990 comes fully into force infertility treatment 
involving IVF and gamete donation will require a 
licence from the Human Fertilisation and Embryology 
Authority. It will be a condition of every treatment 
licence that a woman shall not be treated unless 
account has been taken of the welfare of any child who 
may result, including the need of such a child for a 
father (section 13(5)). Guidance concerning this pro­
vision should appear in the code of practice to be 
devised by the authority (section 25(2)).
If IVF succeeds the doctors could incur liability to 
the HIV positive mother in negligence if they fail to 
inform her of the risk that the pregnancy may accelerate 
the progress of the disease.9 If she wishes to undergo 
the treatment and fully understands and accepts the 
risk then the defence of volenti (consent) would be 
available to the medical team.
d o c t o r s’ l ia b il it y  to  c h il d
According to the Congenital Disabilities (Civil 
Liability) Act 1976 as amended by the Human Fertilis­
ation and Embryology Act 1990, a child born disabled 
can sue whoever has negligently caused the disability. 
The act was introduced in response to the general 
disquiet in the aftermath of the thalidomide case. The
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problems facing those plaintiffs were, firstly, the doubt 
as to whether a child could sue in respect of injuries 
that had occurred before birth and, secondly, the 
difficulties in proving causation—that is, proving that 
the negligence of the pharmaceutical company had 
caused the disability in question. The 1976 act provides 
that a child can sue for a disability where the negligent 
act causing the disability occurred before birth or even 
before conception, and section 44 of the Human 
Fertilisation and Embryology Act 1990 extends liability 
to cover negligent acts done in the course of infertility 
treatments such as IVF, gamete intrafallopian transfer 
(GIFT), or artificial insemination.
It is necessary, however, to distinguish between acts 
by the doctor that have caused disability—for example, 
negligent forceps delivery causing brain damage—and 
those that have caused the child to be born at all—for 
example, negligently failing to diagnose that the child 
is likely to be born with serious handicaps and failing to 
advise on termination of pregnancy. A child would be 
able to succeed against the doctors in the first case but 
not in the second, where the child’s action is known as 
one for “wrongful fife” and is not sustainable as a 
matter of public policy.10
p a r e n t s ’ l ia b il it y  to  c h il d
Finally, the HIV infected child may have a remedy 
against its own parents. Under the 1976 act a father can 
be sued for negligently causing the child’s disability 
but normally the mother cannot. If the father only was 
infected by HIV then provided there is proof of 
paternity it would follow that the child’s infection had 
come from the same source. If, however, both parents 
are infected it may be impossible to show which of 
them had caused the HIV infection in the child, and as 
indicated earlier the 1976 act has established the right 
of a child to claim for prenatal injuries but has not 
provided any means of overcoming the often over­
whelming obstacle of proving causation. In practical 
terms the child is unlikely to bring an action against the 
father because he will not have the means to satisfy a 
successful claim.
Medical ethics
David Seedhouse
Although itself uncommon, this dilemma reflects a 
widespread quandary in medical decision making. 
Whatever the protagonists decide there is every 
possibility that others elsewhere will arrive at contrary 
solutions in similar situations. The problem is that no 
one has yet asked fully the purpose of infertility 
treatment. Until this fundamental question is ad­
dressed, apparently fiendish dilemmas will continue. 
For some the solutions may lie in legal or ethical rights, 
for others in reducing harm to society, and for others in 
egalitarianism. But without overt understanding of 
rationale only ad hoc answers can be expected.
The obvious purpose of treatment is to allow people 
of low fertility to produce children, but there are 
deeper puzzles. Which people: everybody, or only 
those with good chances of success? Which children: 
any child, or only normal children? There is a range 
of possible strategies that might be adopted. For 
example, doctors might choose:
•  To treat people on request
•  To treat all people who might benefit clinically
•  To treat only those people for whom there is a 
probability above a given value that treatment will 
succeed
•  To treat according to any of these criteria but to 
exclude from treatment those people who are them­
selves ill in a way that might directly affect the health of 
the baby
•  To treat according to one of the first three criteria 
but to exclude those people who already have children
•  To treat according to the first three criteria but to 
exclude those not in stable relationships, heterosexual 
relationships, or marriages.
If a methodology for ranking alternatives could be 
agreed then a national system of indicators for treat­
ment could be generated. Many decisions not to treat 
might then cause little controversy (for example, where 
there is no chance of pregnancy, whatever is done or 
where there is high probability of severe handicap) but 
those based in value (the last three criteria given above) 
will remain factious.
By insisting on the consideration of the welfare of 
possible children the law seems to have put the 
responsibility on clinicians to impose personal judg­
ments on potential clients. This is an unacceptable 
burden from the point of view of both doctors (who are 
not trained in such decision making) and patients (who 
are likely to resent unfavourable verdicts). In my 
opinion, the basic principle of infertility treatment 
should be to treat all people who might benefit 
clinically. If resources are scarce then the standard 
ought to be to treat those people for whom there is a 
probability that the treatment will succeed, where the 
value of the probability should fluctuate according to 
availability of treatment (the more restricted the 
service, the higher the probability).
The level of resources in the present case is unclear. 
If they are sufficient then treatment should be offered 
to the couple, who are competent and aware of the 
implications. Where enough resources exist, “best 
interest” judgments made against the wishes of com­
petent people must be avoided.
If resources are limited then account should be taken 
of negative factors, wrhich would include the likelihood 
of success of treatment, the possibility of a diseased 
baby, and the three existing children. If treating this 
couple means that other couples with fewer negative 
factors will be denied help then treatment should be 
refused—clinical considerations should always
take precedence and all judgments of value justified 
thoroughly.
View from the London Fertility Centre
Ian Craft
The second report of the Voluntary Licensing 
Authority (1987) recommended in its guidelines that 
“all patients entering an IVF programme should be 
tested for hepatitis B and HIV antibodies.” The 
reaction to this recommendation provoked such an 
adverse response that subsequent reports have suggested 
this need be mandatory only when donated gametes are 
used, screening both potential donors and recipients.
The London Fertility Centre has introduced a policy 
whereby all new and existing patients undergoing 
assisted conception treatment—including IVF, GIFT? 
and artificial insemination, with and without donated 
gametes—should be tested for both hepatitis B and 
HIV, and this recommendation has the support oflls 
ethics committee. This committee is constituted 
eight lay members and three medical or scientific 
members. Close collaboration exists between d*e 
centre and the consultant medical staff of the referra^ 
medical diagnostics laboratory, who themselves have 
in depth knowledge of the HIV state and disease.
We consider that the policy is prudent with 
increase in HIV prevalence even in the heterose^al 
community. In addition, recent reports have indica^d
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that it is not possible to predict accurately who is at risk 
of HIV infection at the best of times.11 Since the policy 
was introduced no patients have been found to be HIV 
positive, and far from suggesting that the policy should 
be discontinued we think that it should be maintained 
because of the changing trends in scientific reporting.
The dilemma as to whether infertility management 
should be undertaken in couples positive for HIV 
concerns assessing the rights of such infertile couples 
to be treated; the rights of any resultant offspring to be 
free of disease and to have a supportive and longlasting 
family relationship; and the right of the attendant 
medical and laboratory staff to maintain their own 
health, which has particular relevance when IVF, 
GIFT, or artificial insemination is being considered.
Our centre would decline to treat the couple con­
cerned as a matter of policy because we believe that it 
would be irresponsible to put staff members at risk, 
even if this risk is minimal. In addition, we are 
concerned that the incidence of vertical transmission to 
offspring may well turn out to be much higher than is 
currently quoted. Is it really considerate to want to 
have a child in these circumstances?
Our only qualms concerning our decision is whether 
we should be as stringent with the management of a 
couple positive for hepatitis B virus as there is a degree 
of flexibility of treatment in these circumstances. Our 
main reasoning is in part based on the likelihood of the 
child infected with HIV either dying or being orphaned 
by its parents’ early death; with regard to hepatitis B, 
vaccination and passive immunity can be provided to 
the infant.
We also do not consider that couples positive for 
HIV are being treated any differently from others with 
severe life threatening disease in whom fertility treat­
ment would not be advised—for example, those with 
unstable diabetes, severe hypertension, non-Hodgkin’s 
lymphoma, etc.
In any event, we feel that the pregnancy potential of 
the couple reported is likely to be markedly reduced by 
contributory factors—the polycystic ovarian condition 
and suboptimal sperm—despite both partners having 
previously proved their fecundity. Counselling by 
members of the fertility team concerning the contri­
butory relevance of these factors, together with 
supportive counselling of the negative decision, is 
indeed as essential as independent HIV counselling.
Medical viewpoint
Danielle Mercey, Susan Bewley
Such cases are not rare and will increase. Fertile 
or infertile, HIV infected patients need careful 
counselling, within the limits of current knowledge, 
about infectivity, pregnancy, breast feeding, parental 
illness, and death, and ideally this should start before 
initial testing.
HIV may decrease fertility: oligomenorrhoea and 
testicular atrophy have been reported. The rate of 
vertical transmission, from the latest European data, is 
<15% (but it may be different in late stages of HIV 
infection and in Africans). Seventeen per cent of 
infected babies become ill and die under one year, and 
there are insufficient data to predict the fate of the 
remainder. Although it has been postulated that 
pregnancy worsens the mother’s prognosis, no evidence 
has emerged. Drugs used in pregnancy have potential 
adverse effects. Present advice is not to breast feed.
Even if the date of infection were known, the 
prognoses for the parents in this case are difficult to 
assess. The woman has “good” prognostic markers but 
this does not preclude sudden, rapid deterioration.
The results of large cohort survival studies, mainly 
including men, may not apply.. The man has an 
uncertain, but probably worse, prognosis as his T4 
lymphocyte count is low and he is stage IV-C2. The 
exact T4 count, its trend, and the defining diagnosis 
are not given. At best, with current survival, a child 
would have an evens chance of losing two sick parents 
by late childhood. Childcare arrangements during 
illness and after death must be discussed. The risks to 
health care staff are of subordinate concern.
Many couples choose not to have children, and this 
terrible loss compounding the grief of being HIV 
positive should not be underestimated. Genitourinary 
physicians manage most patients with HIV, but they 
are not gynaecologists; if this couple still wants a 
pregnancy they deserve an opinion for information 
about investigations and treatment. Account will then 
be taken of current medical standards and the estimated 
chances of creating a medical catastrophe. We would 
refer them to an infertility specialist but would warn 
this couple that this is not with an expectation of 
receiving treatment.
It might be argued that doctors should simply help 
patients become pregnant if they wish. Although we 
cannot interfere and should not condemn a fertile 
couple who choose to become pregnant, we have no 
positive duty to accede to an infertile couple’s request 
for help. If procedures to make this couple pregnant 
cannot be justified as being in their or the future child’s 
best medical interests then it is wrong to administer 
them.
Caring for patients demands unprejudiced listening, 
empathy, flexibility, and careful negotiations. How­
ever, the duty of care is not “trumped” by autonomy or 
a notion of the right to reproduce. We respect our 
patients’ autonomy within the duty of care, and not for 
its own sake. We are not merely technicians and do 
make hard moral decisions involving a complex 
weighing of considerations, recognising that each 
course of action has personal and ethical costs. Every 
case must be judged on its individual merits and subtle 
nuances, and all the medical factors are relative—not 
absolute—contraindications to aiding conception. 
Whenever we withhold infertility treatment this must 
be a source of painful regret.
Outcome
Mr Smith and colleagues continue: Fertility is a 
basic human desire and it was thus inevitable that an 
HIV infected couple would present for management of 
infertility, particularly when the female partner is well. 
We were unable to draw parallels with any other 
condition because HIV infection is incurable and 
has a long asymptomatic incubation period followed 
by a high probability of death: this is coupled 
with a variable but nevertheless appreciable vertical 
transmission rate.
We have treated a couple in which the woman was 
HIV positive and the man negative, but here the only 
cause of infertility was the use of barrier contraception 
for safer sex. Treatment was artificial insemination by 
husband performed by the husband himself, thus 
removing the gynaecologist from active management. 
This also had the advantage of protecting the HIV 
seronegative husband from potential infection.12
The management of infertility with either medical or 
surgical treatment seemed to us indivisible ethically, 
and although the prescribing of clomiphene is un­
doubtedly technically much easier than, for example, 
performing in vitro fertilisation, the end result is 
essentially the same: the gynaecologist shares the 
responsibility for the potential birth of an infant 
infected with HIV or, if the child is not infected, for its
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likely status as an orphan in the future. It might be 
interesting to consider whether the child could bring 
an action against the gynaecologist for “wrongful life.” 
Consideration should also be given to any risk, 
however slight, of HIV transmission to health care staff 
involved in the care of such patients.13
The obverse viewpoint is that aware, consenting 
patients have the right to determine the course of their 
own child bearing, in much the same fashion as HIV 
infected women can elect to continue with their 
pregnancy rather than have a termination. It is also 
possible that after being refused treatment for infertility 
the couple could present themselves elsewhere and fail 
to disclose their HIV state. For the asymptomatic 
couple it is unlikely that their HIV state would be 
detected.
After careful consideration we did not feel justified 
in managing their infertility. We informed the couple 
of our decision not to undertake active management 
and they accepted this. The couple were also told that it 
was their right to seek a second opinion. We do, 
however, feel that patients deserve sympathetic 
counselling and that an explanation of their infertility 
in selected cases may assist this. We explained to the 
couple that in the future, developments may occur 
which will reduce the vertical transmission rate and
increase fife expectancy, necessitating a change in this 
view. We were careful to make it clear that this was 
unlikely, particularly in th^short term.
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ORIGINAL ARTICLE
Risk factors of female 
HIV-seropositive patients attending the 
clinic for sexually transmitted diseases at 
St Mary's Hospital, London
J R Smith MRCOG, S Murphy MRCPI, J Mellers MB BS, M  James SEN, 
L E M  Osborne MD, M  Byrne MRCOG, P Munday MD FRCOG,
J R W  Harris FRCP and S M  Forster BSc MRCP
Department of Genito-urinary Medicine, St Mary's Hospital, London W2, UK
Summary: Of 3450 women tested for antibodies to human immunodeficiency virus 
HIV-1 and HIV-2 between September 1985 and July 1989, 61 were positive (1.8%). 
Twenty-seven of these (44%) were presumed to have acquired their HTV infection by 
heterosexual contact and 23 (38%) were intravenous drug addicts. In geographical 
origin, 23 (38%) of the patients were from the UK and 19 (31%) from Africa. Amongst 
these 61 women, 2 (3%) have since died, one committed suicide and one was 
suspected of committing suicide.
Keywords: Human im m unodeficiency virus, woman, risk factors, incidence
INTRODUCTION
Between September 1985 and July 1989, 3450 
women who had attending the Department of 
Genito-urinary Medicine at St Mary's Hospital were 
tested for antibody to the human immunodeficiency 
virus (HIV). Of these, 61 (1.8%) were seropositive. 
Although the geographical origin of HIV sero­
positive male patients, their probable mode of 
HIV acquisition and the annual incidence of 
infection are well documented1, these data were 
not available for the HIV-seropositive female 
patients. A retrospective study was therefore 
undertaken.
METHODS
The notes were examined of all HIV-positive 
women who had attended the Department of 
Genito-urinary Medicine at St Mary's Hospital since 
September 1985 when testing for HIV began. Patients 
were selected for testing by offering at booking a 
leaflet explaining the HTV test which they could then 
request if they so wished. In addition to this self 
selection method, 'at risk' patients were offered the 
test. All patients requesting an HIV test were 
counselled by our medical staff and health advisors.
Tests for HTV comprised enzyme-linked immuno­
sorbent assays (ELISA) to detect envelope anti­
bodies to HIV-1 and HTV-2 and p24 antibody 
to HIV-1.
Correspondence to: Dr J R Smith, Department of GU Medicine, 
The Jefferiss Wing, St Mary's Hospital, London W2, UK
,31*
Figure 1. Geographical distribution of the origin of HIV-positive women
RESULTS
Between 1 September 1985 and 31 July 1989, 3450 
women were tested for HIV antibody, of whom 61 
(1.8%) were positive. In 1989, 172 women were 
tested for HTV-2 antibody but none were positive. 
The ages of the HTV-1 antibody-positive patients 
ranged between 17 and 51 years with a mean age 
of 30 years. Two patients have died since the 
diagnosis was made.
Twenty-seven (44%) of the patients were pre­
sumed to have acquired their HIV infection by 
heterosexual contact, 23 (38%) were intravenous 
drug users (TVDUs), 4 (7%) had had blood trans­
fusions and 7 (11%) had no identifiable risk 
factors. Twenty-three (38%) of the patients were 
from the United Kingdom and 19 (31%) were 
African (Figure 1). Of the African patients, 15 (79%) 
were presumed to have contracted their infection
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%Seropositive 
(No. of women tested)
1 9 8 5 1 9 8 6 1 9 8 7 1 9 8 8 1 9 8 9
Year
Figure 2. Number of women tested for HIV each year and number and 
percentage found positive (1985 September to December inclusive only; 
1989 January to July inclusive only)
heterosexually, 3 (16%) had had blood transfusions 
and 1 (5%) was an IVDU. All other IVDUs were 
European. Four IVDUs also worked as prostitutes 
and a small number of IVDUs had had sexual 
contact with HIV-seropositive men.
Figure 2 shows that the number of HIV-positive 
women has increased since 1985. This, however, is 
probably due to the larger number of women tested 
because, apart from 1985, the proportion of HTV- 
seropositive women has remained about the same.
DISCUSSION
At the Department of Genito-urinary Medicine, 
1.8% of women tested for HIV-1 antibody were 
positive. This compares with 11.2% of male patients 
tested over a similar period of time1. This per­
centage, although lower than that for men, is 
larger than the female seroprevalence rates of 0.2% 
to 0.5% reported previously in London2'3. These 
women, however, were attending antenatal clinics 
and, therefore, may be at low risk for HIV. The 
larger proportion of tests which were positive in 
1985 probably reflects a policy of testing only those 
patients who had symptoms of HIV disease. It can 
often prove difficult to assign a single mode of 
transmission to HIV-seropositive women; this is 
especially the case in IVDUs some of whom also 
have HIV-infected heterosexual partners.
Our patients fell largely into two categories, 
namely African patients who acquired the infection 
heterosexually and indigenous patients who 
acquired the infection by intravenous drug usage. 
Thus, with the exception of one drug abuser who 
was an African of European origin, all IVDUs were 
European. Many of the African patients had 
received injections or vaccines in Africa, although 
this is not considered to be a major mode of 
transmission4. None of the prostitutes were HIV 
seropositive in the absence of other risk factors 
although in this series of patients the number of 
prostitutes was small.
Two of the 61 patients (3%) have died since the 
diagnosis, neither directly of HTV infection. One 
committed suicide within one month of diagnosis, 
and the other died within 2 years of diagnosis, due 
to a drug overdose, which may have been suicide. 
A 3% (or even a lesser) suicide rate calls into 
question the efficacy of counselling and psycho­
logical follow-up after the diagnosis of HTV infection, 
when psychiatric morbidity is high in this group of 
women. Suicidal tendency in association with AIDS 
has been reported5 and is a component of intra­
venous drug addiction.
In conclusion, a significant proportion of our 
HIV-seropositive women are African and special 
attention needs to be directed at this population. 
The high rate of suicide amongst HTV-seropositive 
women makes the provision of counselling facilities 
and follow-up essential in all clinic settings where 
HIV testing is offered.
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TABLE H— END-POINTTITRE OF HIV-SPECIFIC ANTIBODY IN 
MATCHED PLASMA AND URINE SPECIM ENS
Sample
Optical density (410  nm) end-point d ilution*
Plasma Urine
1 14 580 16
2 4860 4
3 >43 740 64
4 4860 4
5 1620 1
6 4860 16
7 14 580 1
‘ Reciprocal of highest dilution yielding optical densities over cut-off.
would indicate renal dysfunction. There was an excellent 
correlation between the ELISA result in serum and in urine; even 
so, the low urine antibody dtres create the potential for a 
false-negative result (eg, in seroconverters or in individuals with low 
serum antibody titres). Furthermore, urinary pH and specific 
gravity, the presence of preservatives or bacterial contaminants, and 
storage conditions may compromise antibody stability or recovery 
and lead to a false-negative result. Although these findings are 
promising, additional studies are required before urine testing can 
be a practical screening method.
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Safe sex and conception: a dilemma
S ir ,— W e were consulted by a 26-year-old woman who first tested 
seropositive for HTV-1 in 1988 and her 48-year-old husband. She is 
seronegative for HTV-2. Transmission of HIV-1 was thought to 
have occurred in 1987 heterosexually. The husband has tested 
seronegative for HTV-1 and HTV-2 twice since 1988. Since they 
started sexual relations, the couple had consistently practised safe 
sex to protect the husband. They sought advice about pregnancy 
and over six counselling sessions spread over 6 weeks the facts about 
HTV, vertical transmission, and risks to the mother were provided.
We told the couple that the vertical transmission rate in well* 
, HIV-positive women is unknown but is probably 25-30%,* at least 
in developed in countries; it may be greater if the woman has 
symptoms of HIV infection.2 They were told that it is impossible to 
detect before delivery which babies will have HTV infection and that 
HTV infection in a baby bom to an infected mother is difficult to 
diagnose. Maternal antibodies may persist for up to 18 months, 
producing serological confusion.. For the present we are assuming 
that these babies are not infected j even though no data are available 
yet on the long-term* clinical outcome of this group. Definite HTV 
infection can only b^ j confirmed by the appearance of symptoms or 
positive HTV culture: The risks to the HIV-infected mother are 
unknown, though theoretically pregnancy may precipitate a 
deterioration in her disease.3
After this counselling T4 counts and p24 antigen tests were done; 
the T4 count was normal (0*72 ¥ 10*11) and the p24 antigen was 
negative. Having been given every opportunity to ask questions 
they decided they wanted to have a child. They then pointed out 
that they had been practising safe sex and that they would be unable 
to have children without placing the husband at risk.
After discussion between the genitourinary medicine and 
obstetric departments it was decided to offer artificial insemination 
by husband (AIH), done by the husband himself. The couple were
advised to keep a temperature chan to time ovulation and to have 
safe sex at times other than ovulation. However, at ovulation time 
the husband was requested to produce a semen specimen into a 
sterile pot and to inject this into the high vaginal area via a 5 ml 
syringe and a dextrose quill. Pregnancy is still awaited.
We were reluctant to encourage the pregnancy in view of the risk 
to the child and, possibly, the mother. The couple, however, had 
decided to proceed with pregnancy. Respecting their wishes and 
taking into account the need to protect the husband we felt obliged 
to offer AIH. It seems to us that the proper course for doctors in this 
situation lies in thorough counselling, allowing the couple to make 
an informed decision. Once the couple decides to proceed, doctors 
should do what is required to protea the seronegative male partner. 
We also felt that the husband should carry out the AIH procedure, 
removing the doctor from the act of conception. AIH may have a 
part to play in a small number of HIV seropositive patients, but only 
after extensive counselling.
Departments of Genito-unnary Medicine 
and Obstetrics.
St Mary's Hospital,
London W 2 1 NY. UK
J.R . Sm ith  
P. W. R e g in a l d  
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Mother-to-infant transmission of HIV
S ir,—Dr Goedert and colleagues (Dec 9, p 1351) report that 
analysis of antibody reactivity in sera from HIV-1 transmitting and 
non-transmitting mothers shows a correlation between lack of high 
 ^affinity antibodies to gpl20 HIV envelope protein and infection of 
the offspring. They could not confirm our observation*0 of a 
positive association between the presence of antibodies to epitopes 
of the hypervariable loop of gpl20 and lade of HIV transmission 
from mother to child.
There are significant differences between our studies and 
Goedert and colleagues’ investigations. They use one 24 aminoadd 
peptide for each of five HIV-1 strains covering only part of the 
hypervariable loop. We had recorded that the size and position of 
the peptides used would be of great importance.
We analysed sera from 30 HTV infected mothers who gave birth 
to 19 uninfected and 11 infeaed infants. Criteria for infection/non- 
infection were those of die Centers for Disease Control. In addition, 
several DNA samples from infeaed and non-infected children were 
assayed for HTV viral sequences by the polymerase chain reaction 
with three primer pairs, and results were confirmed by Southern 
blot and fragment restriction analysis. Antibody reactivity was 
assayed in a peptide ELISA with fifteen mer peptides overlapping 
by 10 aminoarids describing most of the structural protein of HTV 
(g a g , erru). Sera were diluted from 1 in 100 to I in 10 000 and tested 
against each peptide in duplicate. Although no significant difference 
was found in reactivity to most of the epitopes tested, sera of 
non-transmitting .mothers consistently reacted with the cysteinc- 
containing peptides of the hypervariable loop. Only 2 of the 
transmitting mothers showed measurable reactivity to the 
conserved sequences C51, C57, C58 (table).
REACTIVITY TO CONSERVED SEQUENCES C 51. C 53, C57, AND
C 58 IN TRANSMITTING AND NON-TRANSMITTING MOTHERS
Synthetic peptides*
Transmitting
mothers
(n -1 1 )
Non­
transmitting 
mothers 
(n -= 19)
Fisher's
exact
test
gp I20/C51-INCTRPNNNTRKSIR 2 11 <005
gp 120/C53-RKSIRIQRGPGRAFV 4 10 NS
gpl20/C57-GNMRQAHCNISRAKW 1 11 <001
gpl20/C58-AHCNISRAKWNNTLK 1 7 NS
’Aminoacia sequences according to Ratner et al.4 NS -  not significant.
I
hh'hh i*i - r.-
TRIAL NO. A = study gp. 
C = control gp.
Date of V i s i t _____ / _______/ _______
Name ...................................... Marital Status
Address .................................  Occupation ..
Country of 
Origin
Tel.No.
Date of Birth
Age
S.ampling Frame 1 = PSC
2 = Obstetric
3 = Gynaecology 
H = DDU
5 = Glasgow
6 = Others
9 = Not available
Country of Origin 1 = UK
2 = Other European
3 = North Africa
4 = Sub-Saharan Africa
5 = Asia
6 = North America
7 = South America
8 = Australasia 
, 9 = Unavailable
Sexual contact in/with someone from above
Details
m o d sv73
- 2-
Past Medical History
* Past STD
1 = yes
2 = no
9 = unavailable
* IV Drug Use
Syphilis
Gonorrhoea 
Chlamydia 
T Vaginalis 
Warts
Candidiasis 
BV (Gardnerella) 
HSV
Hepatitis B
Chancroid/LGV/G/
Others
1 = yes, now
2 = yes, past
3 = no
9 = unavailable
Details of IV drug use
Oral drug abuse
Past & Current Prescribed drugs
-3-
* History of immunosupressive illness or therapy
1 = yes
2 = no
9 = unavailable 
Details ...........................................
* Family History - Cancer 1 = Genital tract
2 = Elsewhere
3 = Both 
1) - None
9 = Unavailable
Family History (Other)
Smoking Number per day
Ex-smoker
1 = yes
2 = no
9 = unavailable
* Alcohol (no. units per week) 1 unit = 1 measure spirits 
£ pint beer 
1 glass wine
Obs. & Gynae. History LMP
Menstrual History
IMB
PCB
Date of last smear
Past gynaecological history & obstetric history
-2 J -
* PARA Live Births
Still Births
Spontaneous Abortion >12/52 
T.O.P.1s
Spontaneous Abortion <12/52 
Details ............................................... .
* Current Contraception
1 — Pill • 10 — Rhythm —
2 = Coil 11 = Vaginal sponge
3 = Condom 12 r Sponge + condom
= Cap/Diaphragm + jelly 13 = Sterilization
5 = Condom + jelly m - Vasectomy
6 = Jelly alone 15 = Vaginal condom
7 = Pill + condom 16 = Other
8 = Cap or Diaphragm + condom 17 = None
9 r Withdrawal 99 Unavailable
Details (Include type of IUCD and OC)
* Have you ever used this form of contraception? 1 = yes
2 = no
9 = Unavailable
Pm Q
Coil Q
Condom Q
Cap/Diaphragm
Jelly £
Sponge J~“
Vaginal Condom
-5-
* Past Cervical Smears 1 = CIN1
2 = CIN2
3 = CIN3
*1 = Warty Change
5 = M alignan cy
6 = O ther
7 = N ever done  
9 = U n a v a ila b le
Details .............................
* Sexual History Age first intercourse
Date last sexual intercourse / /
Details
f\J• . ^
* No. o f  r e g u la r  p a r tn e r s  
i e .  > 2 m onths e t c .
1 = None
2 = 1
3 = 2 -5  
W = 5-10 
5 = > 10 
9 = u n a v a ila b le
* No. o f  c a s u a l p a r tn e r s  
f o r  payment (m o n ey /d ru g s)
1 = None
2 = < 10 
3 = 11-20 
H = 21-100
5 = 1 0 1 -5 0 0
6 = > 500
9 = unavailable
-6-
£
* No. of casual partners 
NOT for payment
1 = None
2 = < 10 
3 = 11-20 
H = 21-100
5 = 101-500
6 = > ^00
9 = unavailable
*
* Sexual Practices
1 = yes
2 = no
9 = unavailable
Oral Sex 
Anal Sex 
Sex Toys
Details
* HIV Risk Partners
1 = yes
2 = no
9 = unavailable
Known positive 
Partner of homosexual 
Partner of haemophiliac 
Partner of IVI user 
Partner of transfusion recip 
Partner of African
,« i
Partner of USA/Haiti
CLINICAL HISTORY AND EXAMINATION
History (include history of STD)
P.V. dis. itch sores
G.U.
C.V.S. Resp
G.I.
-7-
On Examination
S l a ^ s  abd o
' "> —
mouth
c.v.s resp
loins
GC PUS WET DRY
Ur MON
Cx TV
Vog BV
P.V.
Ext. genit. 
Vag.
Cx.
Ut.
Adnex.
.Stage of HIV disease
^ c :
1 = gp i
2 = 2 
3  = 3
1» = iJA
5  = *4B
6 = 4C1
7 = 4C2
8 = MD
9  = 4 E  
9 9  = u n a v a i l a b l e
Details
- 8-
Colposcopy v.,.' • •.
* vulva 1 = None
2 = Aceto-white 
' 3 = warts
= suspicious of malignancy 
5 = other 
9 = unavailable 
Details ..............................
* perianal area 1 = None
2 = Aceto-white . -
3 = warts
4 = suspicious of malignancy
5 = other
9 = unavailable .
Details ........................................
* vagina 1 = None
2 = Aceto-white
3 = warts
4 = suspicious of malignancy
5 = other
9 = unavailable
Details ................................
* cervix 1 = None
2 = Aceto-white
3 = warts
= suspicious of malignancy 
5 = other 
9 = unavailable
Details
* ^ -9-
* Biopsy Taken 1 = Taken
2 = Not taken
9 = Unavailable
Vulva
Cervix
Vagina
Other
* STD present on this examination
1 = yes
2 = no
9 = unavailable
Syphilis 
Gonorrhoea 
Chlamydia 
T. V.
Warts
Candidiasis 
B. V.
H.S.V. 
Hepatitis B 
Chancroid/ 
L.G.V.
G. I.
Others
Details of treatment
Smear 1 = Normal
cytology 2 = Warty change
_3 = CIN1 - mild dysk.
= CIN2 - mod. dysk.
5 = CIN3 - severe dysk.
6 = malignant cells
7 = other 9 = unavailable
-10-
* In Situ 1 = HPV not present
2 = HPV present
9 = not available
* Biopsy 
histology
1 = Normal
2 = Warty change
3 = CIN1 
H = CIN2
5 = CIN3
6 = Microinvasion
7 = Macroinvasion 9 = not available
* Biopsy
In Situ HYB
1 = HPV not present
2 = HPV present
9 = not available
* Abnormal Microscopy 1 = yes
* Chlamydia serology 1 = pos.
2 = neg.
9 = unavailable
2 = no 
GC cultures 
TV 
BV
HSV culutres 
Chlamydia IF 
SB
Hepatitis B 
HSV ab
IgG+
IgM+
HIV ab 
PH = __
P24 ag = ____
P2H ab =
9 = unavailable
TH = 
T8 =
